








ADVANCED MAGNETIC RESONANCE IMAGING OF  
EXTRACELLULAR VOLUME FOR GUIDING LEFT  













A dissertation submitted to the faculty of  
The University of Utah 













Department of Bioengineering 
 





























Copyright © KyungPyo Hong 2016 
 














The dissertation of KyungPyo Hong 
has been approved by the following supervisory committee members: 
 
Daniel Kim , Chair 08/04/2016 
 
Date Approved 
Orly Alter , Member 09/08/2016 
 
Date Approved 
Edward Victor Rebok DiBella , Member 08/04/2016 
 
Date Approved 
Edward W. Hsu , Member 08/04/2016 
 
Date Approved 
Evgueni Gennadiy Kholmovski , Member 08/04/2016 
 
Date Approved 





and by Patrick A. Tresco , Chair/Dean of  
the Department/College/School of Bioengineering 
 








Heart failure (HF) is a significant health care problem in the United States. Many 
patients advance towards end stage HF despite optimal medical therapy. For patients with 
end stage HF, unfortunately, therapeutic options are limited. While heart transplantation 
is the most proven treatment for improving survival, it is only performed in 
approximately 2,500 cases annually due to a shortage of donor hearts. Left ventricular 
assist device (LVAD) implantation is an FDA-approved therapy and is clinically 
indicated for two applications: (i) bridge-to-transplantation (BTT) for patients who are 
awaiting heart transplantation and (ii) destination therapy (DT) for patients who are 
ineligible for heart transplantation. Unexpectedly, patients in BTT and DT experience 
cardiac functional recovery after LVAD-induced unloading, which led to an 
investigational concept called bridge-to-recovery (BTR). For successful clinical 
translation, it is important to identify reliable predictors and discriminate responders from 
non-responders. Myocardial fibrosis, as a marker of adverse structural remodeling, is a 
proven predictor of poor outcomes. Cardiac magnetic resonance (CMR) is a proven and 
safe imaging modality for non-invasive assessment of myocardial fibrosis. Particularly, 
cardiac T1 mapping has been widely used for assessment of diffuse myocardial fibrosis. 
However, current cardiac T1 mapping techniques are unlikely to produce accurate results 
in LVAD candidates due to three obstacles: arrhythmia, limited breath-hold capacity, and 
implantable defibrillators. In response, this dissertation describes the development of new  
iv 
 
cardiac T1 mapping methods that overcome these obstacles. To overcome arrhythmia and 
limited breath-hold capacity, we developed a new arrhythmia-insensitive-rapid (AIR) 
cardiac T1 mapping pulse sequence using a robust saturation radio-frequency (RF) pulse 
that is inherently insensitive to arrhythmia. We also made the AIR pulse sequence rapid 
by acquiring only one proton-density and one T1-weighted image within a short breath-
hold duration of only 2-3 heartbeats. To overcome the challenge of suppressing image 
artifacts induced by implantable defibrillators, we developed a new wideband AIR 
cardiac T1 mapping pulse sequence by incorporating a new saturation RF pulse that 
extends the frequency bandwidth to off-resonant spins induced by defibrillators. The AIR 
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This chapter describes background on heart failure and treatment options, imaging 
biomarkers and magnetic resonance imaging, and the objective of this dissertation. It 
concludes with an overview of the entire dissertation. 
 
1.1 Heart Failure 
1.1.1 What is heart failure? 
Heart failure (HF) is a clinical syndrome that describes structural and/or functional 
ventricular impairments, resulting in poor blood circulation through the body. Various 
etiologies can lead to HF, including hypertensive ventricular hypertrophy, arrhythmia, 
cardiomyopathy, valvular disease, pulmonary hypertension, and/or etc. The common 
symptoms of HF include shortness of breath, chronic coughing, fatigue, nausea, increased 
heart rate, and swelling in the legs and abdomen. Unfortunately, no cure exists for HF. As 
a consequence, the National Institutes of Health (NIH) and American Heart Association 
(AHA) recommend life style changes, medicines, and medical procedures that focus on 





1.1.2 Prevalence and economics of HF in the US 
Approximately 5.7 million Americans are struggling with HF (1-9), where 
approximately 1 million HF patients are admitted to hospitals at the cost of $17.5 billion 
annually (10). Re-hospitalization rate within 30 to 90 days post-discharge is 15% to 50%, 
respectively (11,12). Absolute mortality rate is as high as 50% within 5 years after first 
hospitalization (13). Furthermore, patients who do not respond to advanced medical 
treatments progress towards end-stage HF and have 1-year mortality rates as high as 48% 
(14). The total cost for HF care will increase to $69.7 billion by 2030 (8). 
 
1.1.3 Classification and treatment of HF 
According to the 2013 ACCF/AHA guideline (13), HF can be classified into four 
stages (i.e., stage A, B, C, and D) with progressively worst symptoms as summarized in 
Table 1.1. Particularly, patients who are determined to implant a left ventricular assist 
device (LVAD) are classified as stage D. This dissertation mainly focuses on stage D HF.    
 
1.1.4 End-stage HF 
End-stage HF (i.e., stage D, advanced, or refractory heart failure) is described as a 
persistent deterioration of cardiac function despite maximal medical treatment. Patients 
with end-stage HF also suffer from various symptoms, including fatigue, dyspnea, and 
nausea, even at rest. They have limited treatment options: heart transplantation, LVAD 
implantation, and experimental surgery for active treatment, and palliative care and 
hospice for end-of-life care. For the active treatment, heart transplantation is the gold 





all patients due to a lack of donor hearts. Approximately 2,500 heart transplantations are 
performed annually in the US (15). As an alternative, LVAD implantation is clinically 
indicated for bridge-to-transplantation (temporary) and destination (permanent) therapy. 
LVAD has been shown to improve survival in this cohort of patients (16). Despite its 
high cost (17), LVAD therapy is emerging as an adjunct treatment to heart 
transplantation. Experimental surgery (including those with stem cell delivery) is 
investigational at present. For palliative care, patients will decide on how to balance pain 
management and survival. This dissertation, particularly, will focus on LVAD therapy.    
 
1.1.5 LVAD implantation 
LVAD is a mechanical pump to help blood circulation by propelling blood from the 
left ventricle directly to the aorta (see Figure 1.1). LVAD implantation is an FDA-
approved therapy and clinically indicated for two applications: i) bridge-to-
transplantation (BTT) for patients who are awaiting heart transplantation, and ii) 
destination therapy (DT) for patients who are ineligible for heart transplantation. The 
development of this therapy has progressed over decades and is widely accepted as a 
clinical treatment option (13,18).  
 
1.1.6 LVAD for bridge-to-recovery 
Remarkably, patients in BTT and DT experience myocardial functional recovery after 
LVAD-induced mechanical unloading. This unexpected discovery has led to an 
investigational concept called bridge-to-recovery (BTR). In the latest INTERMACS 





rate was reported as approximately 1% (19). On the other hand, Dr. Stavros Drakos' 
prospective evaluation of 77 non-ischemic cardiomyopathy patients in BTT or DT at the 
University of Utah indicates a much higher recovery rate (~21%) than INTERMACS 
report. The discrepancy between these results may derive from inconsistent measures. 
Nevertheless, there are no measurable predictors for identifying patients who will 
respond to BTR, although possible candidates have been suggested, including age, 
history of HF, etiology, and myocardial fibrosis (20). Of these, myocardial fibrosis is a 
promising predictor to discriminate responders from non-responders. This dissertation 
will seek to develop a new cardiac MRI method for assessment of myocardial fibrosis in 
patients who are scheduled for LVAD implantation (i.e., LVAD candidates). For 
successful clinical translation, this may be an important first step towards testing whether 
pre-existing myocardial fibrosis predicts poor outcome following LVAD implantation.  
 
1.2 Imaging Biomarkers 
1.2.1 Left ventricular ejection fraction 
Left ventricular ejection fraction (LVEF) is an important functional measurement in 
cardiovascular medicine to discriminate HF from other heart diseases and is widely used 
for classification of heart failure. Despite its importance in cardiology, LVEF may be a 
poor predictor of outcomes. 
  
1.2.2 Diffuse myocardial fibrosis 
Myocardial fibrosis is an emerging biomarker of adverse structural remodeling in 





extracellular matrix and is related to tissue stiffness. Increased myocardial fibrosis 
impedes myocardial contraction and relaxation and eventually deteriorates the pumping 
ability of the heart. Focal myocardial fibrosis (i.e., myocardial infarct or scar) is typically 
caused by ischemic heart disease such as coronary artery disease (21), whereas diffuse 
myocardial fibrosis associated with the expansion of extracellular matrix (i.e., myocardial 
interstitial fibrosis) results from various non-ischemic insults (22-26). Aging also affects 
the development of diffuse myocardial fibrosis (27).  
 
1.3 Tests for Measuring Myocardial Fibrosis 
1.3.1 Myocardial biopsy 
Myocardial biopsy is the gold standard method for direct assessment of myocardial 
fibrosis. The procedure is performed invasively by sampling endomyocardial tissues 
through either the internal jugular vein or femoral artery to access the right or left 
ventricles, respectively (28). However, endomyocardial biopsy is rarely indicated for 
clinical purpose, because it is invasive, sensitive to sampling errors, and has complication 
risks.  
 
1.3.2 Blood analysis 
Many molecules in blood serum or plasma have been proposed as biomarkers for the 
quantification of myocardial fibrosis; for example, serum carboxy-terminal telopeptide of 
procollagen type I, amino-terminal propeptide of procollagen type III, MMP-1, -2, and -
9, and TIMP-1 (29). Although these biomarkers are likely useful for the assessment of 





information and are weakly associated with histology (30).    
 
1.3.3 Imaging modalities for direct and indirect assessment of myocardial fibrosis 
Various imaging modalities have been introduced for non-invasive assessment of 
myocardial fibrosis, including echocardiography and magnetic resonance imaging. 
Echocardiography can indirectly measure myocardial fibrosis by measuring acoustic 
properties and tissue deformation. Because myocardial collagen changes ultrasound 
scattering and attenuation, the measurement of peak and cyclic backscatter variation may 
reflect the degree of myocardial fibrosis. Alternatively, because myocardial strain is 
related to collagen deposition, the measurement of tissue Doppler (31) or speckling 
tracking (32) may indirectly represent the degree of myocardial fibrosis. In summary, 
echocardiography is capable of measuring some metrics that indirectly reflect myocardial 
fibrosis.  
Magnetic resonance imaging is emerging as a promising modality for direct 
assessment of myocardial fibrosis. Indeed, it is a hot topic of basic and clinical research. 
More details are explained in the next section.  
 
1.4 Cardiac MRI 
Cardiac magnetic resonance (CMR) is a proven and safe imaging modality for non-
invasively characterizing myocardial fibrosis with advanced techniques such as late 
gadolinium enhancement (LGE)(33), cardiac T1 (longitudinal relaxation time of 
magnetization) mapping (34), and extracellular volume (ECV) fraction calculation (35). 





performed to validate CMR against histology (33,36-45).  
 
1.4.1 LGE imaging 
LGE imaging is the gold standard method for non-invasive assessment of focal 
myocardial viability in ischemic cardiomyopathy and is based on gadolinium-based 
contrast agent (GBCA) kinetic differences between infarcted (i.e., focal fibrosis) and 
normal myocardium (21,33). Fibrosis has a slower wash-in/out rate of fluid than normal 
tissues, thus allowing for higher accumulation of contrast agent at delayed imaging time. 
This difference in contrast agent concentration can be exploited to create a signal contrast 
between focal fibrosis (bright) and normal myocardium (dark) with T1-weighting. 
However, LGE is ineffective for imaging diffuse myocardial fibrosis, because normal and 
fibrous tissues are distributed spatially (refer to Chapter 2).  
   
1.4.2 Cardiac T1 mapping and ECV 
Cardiac T1 mapping and ECV calculation from myocardial and blood T1 values are 
emerging as alternatives for the absolute quantification of diffuse myocardial fibrosis, 
where physiological and structural changes in tissue are correspondingly reflected in 
changes of T1. Post-contrast cardiac T1 mapping technique can directly assess diffuse 
myocardial fibrosis after administration of GBCA, and the results are highly correlated 
with histology (26,37). Nevertheless, the reliability of post-contrast cardiac T1 mapping 
itself is controversial due to its sensitivity to a variety of confounding factors including 
contrast agent type and dosage, acquisition timing, renal function, hematocrit, and 





and post-contrast myocardial and blood T1 values has been suggested as a robust MR 
surrogate for diffuse myocardial fibrosis (35). However, studies investigating cardiac T1 
mapping against ECV calculation are largely lacking (34,46). While ECV has been 
validated as a measure of myocardial fibrosis against histology (40,47,48), it should be 
noted that ECV may be confounded by the presence of edema because it is a measure of 
extracellular volume. For example, in patients with acute myocarditis, ECV will reflect 
both edema and fibrosis.  
 
1.4.3 CMR in LVAD candidates 
A variety of different cardiac T1 mapping techniques are currently available for non-
invasive assessment of diffuse myocardial fibrosis (49-54). Of these, Modified Look-
Locker Inversion recovery (MOLLI) is the most widely used investigational cardiac T1 
mapping technique, which uses inversion recovery (IR) radio-frequency (RF) pulses for 
multiple acquisitions of various T1-weighted images during a breath-hold of 17 heartbeats 
(49). However, the accuracy of the MOLLI, as well as other investigational cardiac T1 
mapping pulse sequences, will be unreliable in LVAD candidates due to these obstacles: 
(a) Irregular heartbeats (arrhythmia): MOLLI cardiac T1 mapping is designed for 
regular heart rhythm and normal heart rate. Synchronized with electrocardiogram, 
MOLLI acquires multiple T1-weighted images at various inversion times (TI) after each 
of three inversion RF pulses. To maintain consistent initial inversion magnetizations, IR 
RF pulses must be applied after achieving full recovery of magnetization (i.e., thermal 
equilibrium). In irregular rhythm, however, magnetization recovery is irregular and 





(b) Limited breath-hold capacity: A pixel-by-pixel high-resolution T1 map is 
calculated by curve-fitting of each pixel along the TI dimension to the Bloch equation 
(refer to Chapter 2). Thus, image registration is an important factor for data fidelity. 
Patients with end-stage HF may have difficulty in holding their breath for 17 heartbeats. 
This will result in image misregistration and consequently  T1 miscalculation.    
(c) Implantable defibrillator (e.g., implantable cardioverter defibrillator (ICD) 
and/or cardiac resynchronization therapy (CRT)): Many patients with end-stage HF 
have an implantable defibrillator as either primary or secondary prevention of sudden 
cardiac death. Although clinical CMR can be performed safely in the presence of an 
implantable defibrillator in a 1.5 T MR system (55), most patients do not undergo CMR 
due to significant image artifacts induced by the defibrillator. Image artifacts are largely 
induced by the generator which shifts a center resonance frequency (i.e., off-resonance) 
as shown in Figure 1.2. A defibrillator will induce off-resonance on the order of 2-6 kHz, 
when it is placed 5-10 cm away from the heart: for example, large off-resonance occurs 
near the device (56). A conventional magnetization preparation RF pulse such as a 
hyperbolic adiabatic inversion pulse has a frequency bandwidth of approximately 1 kHz. 
In the presence of an implantable defibrillator, the inversion pulse cannot uniformly tip 
all spins, because some of the off-resonant spins (  ) are out of the frequency bandwidth 
depending on the distance from the device (Figure 1.2B). We adopted the approach 
proposed by the UCLA group (56) and made our RF pulses wider in RF bandwidth, in 








This dissertation is aimed at developing new CMR T1 mapping pulse sequences for 
assessment of diffuse myocardial fibrosis in patients who are scheduled for LVAD 
implantation, addressing three major obstacles for successful imaging: arrhythmia, 
limited breath-hold capacity, and implantable defibrillators. 
 
1.6 Organization of the Dissertation 
Chapter 2 provides the requisite background on magnetic resonance imaging for 
understanding the rest of this dissertation. Specifically, the measurement of longitudinal 
relaxation time (i.e., T1 mapping) and the role of gadolinium-based contrast agents in 
CMR will be explained.  
Chapter 3 describes a new arrhythmia-insensitive rapid (AIR) cardiac T1 mapping 
pulse sequence, which also serves as the framework for wideband cardiac T1 mapping 
pulse sequence (Chapter 6). The performance of the sequence is evaluated in phantom, 
human, and animal experiments with various heart rhythm and rate conditions. 
Chapter 4 validates the AIR cardiac T1 mapping pulse sequence against histology in a 
longitudinal canine study. Particularly, post-contrast myocardial T1 and ECV 
measurements are acquired in canines to investigate which metric is more strongly 
correlated with histological quantification of diffuse myocardial fibrosis. 
Chapter 5 compares the AIR cardiac T1 mapping pulse sequence against MOLLI in a 
cross-sectional canine study. T1 and ECV measurements acquired by these methods are 
compared to investigate any systematic differences between them. 





assessment of myocardial fibrosis in patients with an implantable defibrillator. As a 
follow-up, this new method is preliminarily tested in subjects implanted with a device.  
Chapter 7 summarizes this dissertation and provides suggestions on future directions.  
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Table 1.1. AHA classification of HF with treatments. Summarized from Yancy CW et 
al., JACC 2013. ICD, implantable cardioverter defibrillator; CRT, cardiac 



















Figure 1.1 An example of LVAD installation in human. Picture from 
https://www.nhlbi.nih.gov/health/health-topics/topics/vad. Source: National 
Heart, Lung, and Blood Institute; National Institutes of Health; U.S. 















Figure 1.2. RF pulse coverage (gray dome) in the absence (A) and presence (B and C) 
of an implantable defibrillator. In the presence of a device, the degree of off-resonance 
(  ) is inversely proportional to the distance from the device. Conventional RF pulse 
(1 kHz) cannot excite both on- and off-resonance of fat and water frequencies (B), 






BACKGROUND ON CARDIAC MRI 
 
This chapter provides background on magnetic resonance imaging (MRI). For more 
details, the readers are referred to the literature.  
 
2.1 Introduction 
MRI is a safe imaging modality that is used routinely in clinical radiology. It is based 
on nuclear magnetic resonance (NMR) of nuclei placed in a static magnetic field. The 
main concept of MRI is to generate, manipulate, and detect the transverse magnetization 
of spins in the tissues of interest by encoding spatial information (i.e., spatial resonance 
frequency) and then reconstructing images through Fourier transformation of the detected 
signals.  
 
2.2 Nuclear Magnetic Resonance 
2.2.1 Nuclear spin 
Spin is an angular momentum (  ) observed in nuclei of atoms which have odd atomic 
weights and/or odd atomic numbers. A nucleus has a magnetic dipole moment (  ) if it 








P). The relation between spin angular 





gyromagnetic ratio. The magnitude of    is           where   is Plank's constant   






P). For this dissertation, proton (
1
H) will be focused on, because the 
human and animal body are mostly made up of water (H2O) and hydrocarbon 
compounds.  
 
2.2.2 Magnetization in static magnetic field (       ) 
Once spins are placed in a strong static magnetic field (        ), they are aligned in the 
same direction as the magnetic field and expressed as magnetization (     ) which is a 
vector field representing comprehensive spins:           (refer to Figure 2.1). In the 
magnetic field, the spins precess at a resonance frequency (  ) known as the Larmor 
frequency:  
      . 
The gyromagnetic ratio ( ) is specified by the nuclei. For example,      for the protons 
(
1
H) is 42.58 MHz/T. Magnetization at the thermal equilibrium state in the magnetic field 
is expressed as:  
                
              
    
 
where    is the total number of spins,    is absolute temperature, and   is Boltzmann's 
constant (              ). Practically, the magnitude of      can be controlled by the 







2.2.3 Radio-frequency pulse  
A radio-frequency (RF) pulse generates an RF field (        ) to rotate the longitudinal 
magnetization onto the transverse plane for signal detection as illustrated in Figures 2.1 
and 2.2. Its frequency is tuned to the resonance frequency of the spins (i.e., resonance 
condition,       ):   
              
            
where   
     is a pulse envelope function. A          (transverse plane) is perpendicular to the 
         (longitudinal). An RF pulse can be applied to spins with a certain flip angle ( ) and at 
a certain location (see Section 2.3.1). Flip angle is determined by the duration ( ) and the 
magnitude of         :       
      
 
 
. Therefore, the strength of an RF pulse (i.e., RF 
energy) is associated with both the magnitude of the          and the duration of the RF pulse. 
Specific absorption rate (SAR) is a measure of energy deposition rate in the human body 
by an RF pulse and is an important factor of MR safety, in that RF energy transferred 
directly to a subject causes increasing temperature in the tissues. According to FDA 
guidelines, the normal SAR limit is less than 2.0 W/kg whole-body or a core temperature 
increase of 0.5 ˚C.   
When no RF pulse is applied, magnetization is maintained at the thermal equilibrium 
state (               ), and its direction is identical to that of         . Once an RF pulse is applied, 
the magnetization points to the other direction and begins to recover back to the initial 
state (or thermal equilibrium) while precessing at the Larmor frequency about         , which 







2.2.4 RF transmitter/receiver coil 
An RF coil is used as an antenna for both transmitting RF energy into a subject to 
stimulate spins and receiving/detecting MR signals from the excited spins. Particularly, 
based on Faraday's law of induction (i.e., electromagnetic induction), the recordable MR 
signals are generated mostly from the transverse magnetization relaxation (   ) of a 
FID.  
 
2.2.5 Longitudinal relaxation time (T1) 
Longitudinal relaxation time (T1) is a time constant describing the recovery rate of 
longitudinal magnetization (  ) back to thermal equilibrium after the magnetization has 
been rotated onto the transverse plane. Because the time constant T1 is highly associated 
with the surrounding environment (spin-lattice relaxation), tissues with different 
compositions have different T1 values. The spin-lattice relaxation is explained by the 
energy exchange or dissipation between spins and their surroundings.  
The Bloch equation (1) describes the longitudinal relaxation mechanism through 
mathematics (refer to Figure 2.3):        
   
  
  
       
  
 
→                     
                   
      
For example, when an inversion recovery (IR) RF pulse (magnetization is flipped by 
180˚) is applied,            is       and            becomes          
      . On the other 
hand, when a saturation recovery (SR) RF pulse (magnetization is flipped by 90˚) is 
applied,             is 0 and             becomes         





         after SR RF excitation recovers to 63% of the thermal equilibrium state,    .   
 
2.2.6 Transverse relaxation time (T2) 
Transverse relaxation time (T2) is a time constant describing the loss rate of phase 
coherence (spin-spin relaxation) of transverse magnetization (            ) after RF excitation. 
As mentioned in Section 2.2.4, the transverse magnetization is the recordable source of 
an MR signal, and its amplitude depends on the degree of coherence of isochromates. As 
spins are dephasing, the intensity of the transverse signal accordingly goes down (i.e., 
highest when in phase, lowest when out of phase). The time constant T2 is largely 
independent of the strength of the magnetic field.     
The Bloch equation also describes the transverse relaxation mechanism through 
mathematics (refer to Figure 2.3): 
    
  
  
   
  
 
→                                 
      
After one time constant (  ),             decays to 37% of               . 
 
2.3 MR Imaging 
Utilizing the fundamental properties of NMR phenomena, MR signals can be non-
invasively detected from the inside of a living subject in a strong magnetic field. 
However, the reconstruction of a visible image from the detected signals is not simple, 
because there is no localizing information in the main magnetic field. For example, all 





homogenous magnetic field. After RF excitation of all spins, the detected MR signals 
have a single resonance frequency: i.e., it is impossible to distinguish where the signals 
came from. Thus, after the development of signal localization, MRI has been an 
invaluable technique for non-invasively exploring arbitrary cross-sections in living 
subjects.  
 
2.3.1 Localization of MR signals 
Localization is achieved by using a gradient field (    ) generated by gradient coils 
(refer to Figure 2.1). For 3-dimensional localization, slice selection and spatial encoding 
(phase and frequency encoding) are performed. First, slice selection is determined by a 
linear gradient field with the bandwidth of a transmitting RF pulse. For example, a slice 
perpendicular to z-direction can be selected by a modified magnetic field with an extra 
gradient field:                , where   is the location of the slice in z-direction and 
   is the magnitude of z-gradient field. Correspondingly, the resonance frequency in the 
slice is modified along z-direction:                      . Note that the slice 
thickness can be determined by the range of   (e.g., from    to   ), and the bandwidth 
(BW) of an RF pulse is:                                . By 
incorporating these two into an RF pulse and applying it to a subject, spins in the selected 
slice are ready for MR imaging.   
Frequency and phase encoding enable the localization of 2-dimensional (2D) 
information in the slice selected by the z-gradient. When recoding MR signals (FID) in 
the x-y plane, the application of a linear gradient field along the x-direction, like slice 





                . Each location can have a slightly different resonance 
frequency. For y-direction encoding, a certain degree of phase shift can identify the 
location of the magnetization by applying a linear gradient field along the y-direction 
before frequency encoding. The combination of these two encoding techniques can 
localize the magnetization in the 2D imaging slice selected by the z-gradient field. Figure 
2.4 shows an example of the localization scheme to generate spatial MR signals in a spin 
echo pulse sequence. First, a z-gradient is applied with an RF pulse (90˚) to select an 
imaging slice, and then after phase encoding followed by another z-gradient and RF pulse 
(180˚), the MR signal (FID or echo) is recorded with frequency encoding at an echo time 
(TE). To sweep over the y-direction, this process is repeated periodically after the 
repetition time (TR). These MR signals,     , are stored in a k-space for image 
reconstruction after Fourier transformation.      
 
2.3.2 Image reconstruction 
k-space,       , is a spatial frequency domain filled with the Fourier transformation of 
measured MR signals,     , and its values are complex numbers with the unit of cycle 
per millimeter. For a 2D image such as in the x-y plane, the fundamental imaging 
equation associated with        is:  
                        







where        is an expected image,       
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Thus, the inverse Fourier transform of        yields the image        encoded by the MRI 





2.3.3 T1-weighted imaging  
T1-weighted imaging is one of the basic MRI techniques and utilizes the difference in 
T1 relaxation times of different tissues. By setting a short TR and TE in a MR pulse 
sequence, the intensity difference (image contrast) between different tissues is achieved 
in the T1-weighted image. The short TR maximizes the contrast between tissues, and the 
short TE minimizes T2 effects (refer to Figure 2.3). Because T1-weighted imaging 
techniques mostly acquire the degree of T1 relaxation with minimized T2 effects, it is 
typically used to explore T1 times. On the other hand, T2-weighted imaging uses a 
relatively long TR and TE. The long TR minimizes T1 effects, and the long TE 
maximizes image contrast between tissues (refer to Figure 2.3). This can be used to 
investigate T2 times.   
 
2.4 Cardiac T1 Mapping 
The conventional method for measuring T1 relaxation time is to trace the change in 
intensity along the relaxation of longitudinal magnetization (Mz) at different inversion 
times (TI) after IR or SR RF excitation, using a T1-weighted imaging technique. Then the 
T1 can be calculated through curve fitting to the Bloch equation describing an IR or SR 
experiment.    
As MR techniques advance, a variety of high-resolution pixel-by-pixel T1 mapping 
methods for cardiovascular MRI are available within a single breath-hold (2-7). From a 
clinical perspective, T1 mapping enables tissue characterization and observation of 
physiological changes, because the unique composition of different tissues is directly 





kidney at 3 Tesla are approximately 812, 1471, 1932, and 1194 ms, respectively (8). The 
widely used investigational cardiac T1 mapping pulse sequence is MOLLI using IR RF 
pulses (2), which acquires multiple single-shot T1-weighted images (11 images) at 
different TIs within a single breath-hold (17 heartbeats). For calculation of a pixel-by-
pixel T1 map, MOLLI utilizes a three parameter non-linear curve fitting method in each 
pixel;                     (2).  
 
2.5 MRI Contrast Agents and Extracellular Volume Fraction 
MRI contrast agents are utilized to improve image contrast during MR acquisitions 
and can be made of gadolinium-based (Gd, paramagnetic) compounds that mainly 
shorten the T1 relaxation time. For clinical purposes, Gd contrast agents (or GBCA)(e.g., 
gadobenate (MultiHance) and gadoteridol (ProHance)) are administrated intravenously, 
and then they distribute to the extracellular space: i.e., they are extracellular contrast 
agents.  
 
2.5.1 Decreasing native longitudinal relaxation time  
Gd contrast agents decrease the native longitudinal relaxation time (T1) by 
accelerating the energy transfer between interacting, 7 unpaired Gd electrons and 
surrounding protons. According to the kinetics of Gd contrast agents (9,10), the 
difference between the post- and pre-contrast longitudinal relaxation rate (       ) is 
linearly proportional to the concentration of Gd: 
    
 
       
 
 
      





where   is the relaxivity of the contrast agent and      is the concentration. In other 
words, MR properties are changed in tissues before and after the administration of Gd 
contrast agents. As a result, new image contrast mechanisms are available. A 
representative technique is called late gadolinium enhanced (LGE) imaging (see Section 
2.5.2). Also, the quantification of the extracellular spaces in the myocardium can be 
estimated after administration of Gd (see Section 2.5.3).   
 
2.5.2 Late gadolinium enhanced imaging  
LGE MR imaging is a gold standard technique for non-invasive assessment of tissue 
viability after Gd injection (11,12). LGE utilizes the T1-weighted imaging technique, 
based on changed longitudinal relaxation times in tissues. Damaged or infarcted tissues 
have different contrast agent kinetics compared to normal tissues; the wash-in/out rate of 
contrast agent may be slow in the damaged tissues. This difference in Gd kinetics can 
change post-contrast T1 times in tissues and enable acquisition of enhanced contrast 
images between normal and damaged tissues. The signals from damaged tissues can be 
relatively maximized by acquiring a T1-weighed image at the zero-crossing moment of 
normal myocardial T1 relaxation after applying an IR pulse. As a result, the image 
intensity in normal tissues can be null (dark) as a reference, whereas that in damaged 
tissues becomes bright because damaged tissues have faster T1 relaxation times than 
normal tissues (i.e., a higher concentration of Gd in damaged tissues). Therefore, LGE 







2.5.3 Extracellular volume fraction  
Based on Gd kinetics, extracellular volume fraction (ECV) can be measured non-
invasively through cardiac T1 measurements. At the equilibrium state of concentration 
after Gd injection (i.e., identical molar concentration per unit volume in tissues), the ratio 
of the concentration in myocardium to the concentration in blood is expressed as (13-15): 
              
         
 
             
        
 
   
              
 
where           . Note that Gd contrast agents can permeate into extracellular 
spaces due to their small molecular size relative to the capillary wall pore. Therefore, 
ECV in myocardium can be non-invasively calculated from pre- and post-contrast 
myocardial and blood T1 values with hematocrit correction at the equilibrium state of Gd 
in tissues. ECV measurement is highly associated with the observation of structural 
remodeling in the myocardium such as from the accumulation of fibrosis or the 
expansion of extracellular space.  
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Figure 2.1. Simplified MRI system and net magnetization (     ) in a static magnetic 








Figure 2.2. Process of MR signal (FID) generation. M = net magnetization;    = 








Figure 2.3. Behavior of longitudinal relaxation         (left) after SR RF excitation and 
transverse relaxation              (right) in two different tissues. TR = repetition time; TE = 














ARRHYTHMIA-INSENSITIVE RAPID (AIR) CARDIAC  
T1 MAPPING PULSE SEQUENCE 
 
This chapter describes the development of Arrhythmia-Insensitive Rapid (AIR) 
cardiac T1 mapping pulse sequence, which is based on use of a robust saturation RF pulse 
to achieve uniform T1 weighting, without regard to B0 and B1 inhomogeneities. The AIR 
method is inherently insensitive to irregular heart rhythms and acquires a T1 map within 
2-3 heartbeats, depending on heart rate. This work was published in "Arrhythmia-
Insensitive Rapid Cardiac T1 mapping Pulse Sequence" Magnetic Resonance in Medicine 




Cardiovascular magnetic resonance (CMR) is a rapidly evolving modality for non-
invasive assessment of myocardial viability. In particular, late gadolinium enhancement 
(LGE) MRI (1,2) is now considered the gold standard for imaging myocardial viability. 
The LGE mechanism is largely based on delayed washout of the contrast agent in 
enlarged extracellular space containing scarred and/or fibrotic myocardium compared 





administration will exhibit “hyper-enhancement” of scarred or fibrotic myocardium.  
While the LGE MRI method allows for accurate assessment of focal fibrosis, it is less 
reliable for assessment of diffuse fibrosis (3), because it requires a normal reference 
tissue to distinguish the fibrosis. Another inherent limitation with LGE MRI is that its 
data acquisition is typically performed with surface radio-frequency (RF) receiver coils. 
As such, LGE MRI signal is contaminated with surface coil effects (e.g., signal 
inhomogeneity unrelated to LGE). This inherent limitation hinders accurate identification 
of “border” or “gray” zones in myocardial infarction.  
This study was motivated by a clinical need for developing a rapid non-invasive 
method to quantify diffuse fibrosis, which can arise from a number of cardiomyopathies 
(3) including: arrhythmias such as atrial fibrillation (AF), hypertension, diabetes mellitus, 
chronic renal insufficiency, myocarditis and other inflammatory diseases (4-15). LGE T1 
mapping overcomes the limitations of conventional LGE MRI because the measured T1 is 
directly correlated with the contrast agent concentration in the enlarged extracellular 
space containing fibrosis.  Therefore, LGE T1 mapping provides a means to detect diffuse 
fibrosis and quantify its severity.  
The most widely used cardiac T1 mapping pulse sequence is the modified Look-
Locker (LL) inversion recovery (MOLLI)(16). This pulse sequence acquires 11 single-
shot images with different inversion times (TI) within a single breath-hold of 17 
heartbeats (16,17). While MOLLI has been an important development in CMR, it has 
several known limitations. First, MOLLI uses an inversion-recovery (IR) pulse, which is 
inherently sensitive to heart rate and rhythm (18,19). Second, MOLLI is susceptible to T2 





readout (18,19). Third, MOLLI requires long breath-hold duration (~17 s), which is not 
conducive for whole heart imaging in a clinical setting.   
Other cardiac T1 mapping methods have been presented to partially overcome the 
limitations of MOLLI. Piechnik et al. proposed a shortened MOLLI (shMOLLI) 
sequence (20) which acquires 7 single-shot images with different TI values in a single 
breath-hold duration of 9 heart beats. However, shMOLLI, as a LL method, is still 
sensitive to T2 effects, and it may be desirable to further decrease the scan time for higher 
clinical throughput. A modified LL acquisition with saturation recovery (MLLSR) 
technique uses an saturation-recovery (SR) pulse instead of an IR pulse to make the pulse 
sequence insensitive to heart rate and rhythm (17). However, MLLSR, as a LL method, is 
sensitive to T2 effects, and has a relatively long scan time. A non-LL method based on SR 
magnetization preparation acquires multiple single-shot images with different SR time 
delays (TD), where each image acquisition is preceded by an SR pulse to minimize the 
sensitivity to T2 effects (18,21). However, this method has a relatively long scan time.  
We present a rapid cardiac T1 mapping pulse sequence based on two single-shot 
image acquisitions (22): i) "proton density-weighted" (PD) image and ii) T1-weighted 
(T1w) image with recovery time on the order of T1. This radio-frequency field (B1) 
insensitive T1 mapping approach with only two image acquisitions has been 
demonstrated in hip cartilage (23) and cardiac (22) applications at 3T. This study expands 
upon our prior work (22) with b-SSFP readout for increased signal-to-noise ratio (SNR). 
The proposed pulse sequence is inherently insensitive to heart rate and rhythm 
conditions, due to SR magnetization preparation, and T2 effects, due to T1 calculation 





ramp-up RF pulses are similar for both PD and T1w images and cancel out during T1 
calculation), and permits whole heart coverage in a clinically acceptable scan time. The 
purposes of this study were to develop an arrhythmia-insensitive, rapid (AIR) T1 mapping 
pulse sequence and evaluate its performance against MOLLI and reference T1 mapping 
method in in vitro and in vivo experiments. 
 
3.2 Materials and Methods 
3.2.1 IR vs. SR for cardiac T1 mapping 
The MOLLI T1 mapping method based on IR T1 weighting is sensitive to heart rate 
and rhythm, because the longitudinal magnetization (Mz) immediately after the IR pulse 
depends on the prior history of Mz recovery affected by heart rate and rhythm. In 
contrast, AIR T1 mapping based on SR T1 weighting is insensitive to heart rate and 
rhythm, because the Mz immediately after the SR pulse is always zero. This assumption 
is only valid when using a robust SR pulse (see below for more details). Figure 3.1 shows 
plots of Mz curves of the IR and SR pulses for three irregular heartbeats which illustrate 
this concept. Note that T1 is calculated based on these curves. Another advantage of an 
SR pulse over an IR pulse for cardiac T1 mapping is that it is more adaptable for rapid T1 
mapping (e.g., T1 calculation based on two single-shot images), because the Mz is always 
positive. Note that for an IR acquisition, several IR image acquisitions are typically 








3.2.2 Cardiac T1 measurement based on two single-shot image acquisitions 
We propose to acquire two single-shot b-SSFP images, where T1 is calculated from a 
ratio of T1w and PD images to cancel T2 effects. We elected to use TD = 600 ms, based 
on our prior experience with LGE cardiac T1 on the order of 600-800 ms, to achieve a 
good balance between T1 sensitivity and SNR for the T1w acquisition (24), as illustrated 
in Figure 3.2. The theoretical sensitivity analysis (Fig. 3.2B) shows that the signal 
(Mz/M0) is sensitive to clinically relevant T1 ranging from 263-2000 ms, where M0 is the 
equilibrium magnetization. In the proposed T1w acquisition with TD = 600 ms, tissues 
with short T1 values (< 300 ms) are susceptible to noise, due to near complete recovery of 
Mz (i.e., Mz/M0 > 0.86), whereas tissues with long T1 values (>2400 ms) are susceptible 
to noise, due to insufficient recovery of Mz (i.e., Mz/M0 < 0.22).  With TD = 600 ms and 
temporal resolution of b-SSFP readout = 217 ms, our total scan time per image is 832 ms 
(see 3.2.5 Pulse Sequence for details). As such, for heart rates ≤ 73 beats per min (bpm), 
we acquired the single-shot PD and T1w images at late diastole in two heart beats. For 
heart rates > 73 bpm, we acquired the PD and T1w images at late diastole in three heart 
beats, as shown in Figure 3.3. For efficiency, we acquired PD images first, to ensure that 
initial Mz is equal to M0, and T1w images second, since initial Mz for the T1w image is 
determined by the SR pulse and TD only (i.e., initial Mz prior to the SR pulse is 
irrelevant).    
With these conditions, T1 can be calculated pixel-wise by dividing the T1w image, 
IT1W, by the PD image, IPD, to correct for the unknown M0 and then solving the Bloch 
equation governing T1 relaxation describing the ideal SR experiment:  
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3.2.3 Effects of dummy RF pulses on T1 calculation 
We used 30 dummy ramp-up RF pulses with flip angles ramping from 0.2 to 34.7 
(i.e., Kaiser Bessel) to minimize the oscillation of magnetization prior to b-SSFP 
imaging. These dummy RF pulses introduce additional T1 and T2 weighting onto both 
"PD" and T1w images. We determined their effects by performing a numerical simulation 
using the Bloch equations governing T1 and T2 relaxations. For the simulation, we used 
the following conditions to achieve clinically relevant T1 and T2 values: pre-contrast 
myocardial T1 = 1471 ms (25) and T2 = 47 ms (26), longitudinal relaxivity (r1) = 5.5 
L/mmol/s (27), transverse relaxivity (r2) = 11.0 L/mmol/s (27), R1 = R1,0 + r1 × [Gd], and 
R2 = R2,0 + r2 × [Gd], where R1,0 is pre-contrast longitudinal relaxation rate, R2,0 is pre-
contrast transverse relaxation rate, and [Gd] is the concentration of Gd-BOPTA 
(MultiHance)(Bracco Diagnostics Inc., Princeton, NJ). We varied [Gd] from 0 to 0.3 mM 
to achieve clinically relevant T1 ranging from 429 to 1471 ms, with matching T2 ranging 
from 41 to 47 ms. For each T1-T2 pair, we calculated Mz immediately prior to PD and 
T1w images. We then took divided the ratio of Mz,T1/Mz,PD (including ramp-up pulses) by 
the ideal ratio of Mz,T1/Mz,PD (without ramp-up pulses). Using Eq. [3.2], we also 
calculated the T1 using the ratio of Mz,T1/Mz,PD including ramp-up pulses, and divided 








3.2.4 MRI hardware 
Both MOLLI and AIR pulse sequences were implemented on two 3T whole-body 
MRI scanners (Tim Trio and Verio, Siemens Healthcare, Erlangen, Germany) equipped 
with a gradient system capable of achieving a maximum gradient strength of 45 mT/m 
and a slew rate of 200 T/m/s. The RF excitation was performed using the body coil. For 
phantom and goat MRI experiments conducted on the Tim Trio system, a 6-element body 
matrix coil array and a spine coil array (with only 6 elements on) were employed for 
signal reception. For canine and human experiments conducted on the Verio system, a 
32-element cardiac coil (RAPID MR International, Columbus, OH) was used for signal 
reception.  
 
3.2.5 Pulse sequence  
The following parameters were used for both MOLLI and AIR in vivo data 
acquisitions: TR = 2.7 ms, TE = 1.1 ms, acquisition matrix = 192 (readout) × 144, slice 
thickness = 8 mm, flip angle = 35º , field of view (FOV) = 340 mm (readout) ×  255 mm, 
GRAPPA parallel imaging factor R = 1.8, receiver bandwidth = 930 Hz/pixel, and 
temporal resolution = 217 ms. The MOLLI acquisition was performed in a breath-hold of 
17 heart beats, using TI values as specified by Messroghli et al. (16) and linear k-space 
ordering. The AIR image acquisition was performed in a breath-hold of 2-3 heart beats 
(see Figure 3.3), depending on the heart rate, with TD = 600 ms, centric k-space ordering, 
and 30 dummy ramp-up RF pulses. Note that centric k-space ordering minimizes 
sensitivity to flip angle variation (28-30).   





T1 weighting within the heart at 3T, which has been shown to yield residual Mz < 2% of 
M0 (31). The hybrid adiabatic-rectangular pulse train is comprised of three non-selective 
RF pulses: non-selective rectangular 140° pulse, non-selective rectangular 90° pulse, and 
non-selective adiabatic half-passage pulse. The crusher gradients inserted between RF 
pulses are cycled to eliminate stimulated echoes. Spoiler gradients are applied before the 
first RF pulse and after the third RF pulse to dephase the transverse magnetization. This 
B1-insensitive SR pulse has been utilized for several applications at 3T, including cardiac 
T1 mapping (28), hip cartilage T1 mapping (23), cardiac B1+ mapping (29), and 
quantitative, cardiac first-pass perfusion MRI (30). 
 
3.2.6 Phantom studies 
We made nine distilled water phantoms with different concentrations of 
manganese(II) chloride ranging from 0.016 - 0.183 mM, to produce a range of clinically 
relevant T1 values (~500 – 2000 ms) in the heart at 3T (see Table 3.1). Manganese 
Chloride was chosen because it has T1/T2 >> 1. The nine phantoms were positioned 
inside a bath to minimize susceptibility effects. The bath contained sufficient amount of 
manganese chloride to minimize artifacts due to T2 effects.  
For reference T1 measurements, an IR fast spin-echo (FSE) pulse sequence (IR-FSE) 
was used to acquire one PD image and 10 images with different TI values (TI = 100, 300, 
500, 700, 900, 1100, 1300, 1500, 1700, 1900 ms). Relevant imaging parameters for IR-
FSE include: FOV = 340 mm × 255 mm, acquisition matrix = 192 × 144, receiver 
bandwidth = 930 Hz/ pixel, TE = 5.1 ms, TR = 11s, and turbo factor = 7. For reference T2 





turbo factor of 2 was used (25). Relevant imaging parameters for the multi-echo FSE 
include: FOV = 340 mm × 255 mm, acquisition matrix = 192 × 144, TR = 1 s, receiver 
bandwidth = 501 Hz/ pixel, refocusing flip angle = 180, and echo spacing = 5.1 ms, and 
12 images with TE values ranging from 10.2 to 122.4 ms (10.2 ms steps). 
To assess repeatability, MOLLI and AIR acquisitions were repeated 10 times at 
simulated heart rate and rhythm conditions of 60 bpm, 120 bpm, and arrhythmia using an 
electrocardiogram (ECG) triggering device. Constant heart rhythms at 60 and 120 bpm 
were simulated using Siemens' patient monitoring unit (PMU) simulator. For arrhythmia 
simulation, a customized ECG triggering device was used to generate trigger pulses at 
times at 0, 400, 1100, 1600, 2500, 3000, 4000, 4400, and 4900 ms, and repeated 
throughout to achieve an effective heart rate of 111 bpm, which were inputted to 
Siemens' PMU. For each heart rate and rhythm condition, the correct ECG trigger times 
were stamped onto the dicoms via the PMU. Using the IR-FSE as the reference, T1 
accuracy and precision were assessed by calculating normalized root-mean-square-error 
(NRMSE) and coefficient of variation (CV). 
  
3.2.7 Human studies 
Nine clinical patients with known history of AF (7 males and 1 female; mean age 57 
± 16 years; mean weight 80.48 ± 14.53 kg) and one healthy male subject (age = 38 years) 
were imaged in a mid-ventricular short-axis plane pre-contrast and 5, 10, and 15 min after 
administration of 0.1 mmol/kg of Gd-BOPTA. T1 measurements were made at multiple 
time points after the contrast agent administration to increase the number of samples. 





patients are typically cardioverted immediately prior to clinical MRI examination. Image 
acquisition parameters for MOLLI and AIR were the same as described above, except for 
FOV = 350 mm × 262 mm. Image acquisition order of MOLLI and AIR was randomized 
to minimize bias due to their slightly different imaging time relative to the contrast agent 
administration time. Human imaging was performed in accordance with protocols 
approved by our Institutional Review Board; all subjects provided written informed 
consent. 
 
3.2.8 Animal studies  
Eight mongrel dogs (6 male, 2 female; mean weight 26.9 ± 4.4 kg) and nine male 
goats (mean weight 36.1 ± 10.4 kg) were implanted with a pacemaker in the right atrium 
to induce chronic AF through rapid atrial pacing. Animals were prescribed orally digoxin 
(0.0625 mg, once daily) and metoprolol (25-100 mg, twice daily) to control the 
ventricular rate to less than 150 bpm.  These animals models with chronic AF were used 
in a longitudinal study aimed at characterizing the structural changes associated with AF. 
These animals were cardioverted immediately prior to MRI. MOLLI and AIR T1 
mapping pulse sequences were added to an existing animal MRI protocol. Dogs and goats 
were fasted for a minimum of 12 hours before MRI.  Both species were anesthetized with 
propofol (5-8 mg/kg, IV) for intubation. Throughout MRI experiment, animals were 
ventilated and maintained in a surgical plane of anesthesia with 1.5-3% isoflurane. 
 Ventilation was controlled using a ventilator (DRE Premier XP MRI-Compatible 
Veterinary Anesthesia Machine, DRE Veterinary, Louisville, KY).  A tube was inserted 





conducted with the dogs in lateral recumbency and the goats in a sternal position. 
Anterior and posterior RF receiver coils were positioned to cover the heart.  Heart rate, 
core body temperature, blood pressure, end-tidal CO2, and oxygen saturation were 
continuously monitored and maintained within normal ranges.  Animal imaging was 
performed in accordance with protocols approved by the Institutional Animal Care and 
Use Committee.  
MOLLI and AIR T1 mapping scans were performed using the same protocol as the 
human scans, except for FOV = 280 mm × 180 mm and 0.15 mmol/kg of Gd-BOPTA 
administration. T1 measurements were made in a mid-ventricular short-axis plane pre-
contrast and 5, 10, and 15 min after contrast agent administration. Image acquisition 
order of MOLLI and AIR was randomized to minimize bias due to their slightly different 
imaging times relative to the contrast agent administration time. To assess inter-scan 
variability, we repeated both MOLLI and AIR acquisitions in all 17 animals, without 
repositioning.  
 
3.2.9 Image analysis 
T2 of the phantoms was calculated by non-linear least square fitting (Levenberg-
Marquardt) for three parameters of the signal relaxation equation  (M0, T2, noise) (25,32). 
T1 of the phantoms was calculated by non-linear least square fitting for two parameters of 
the IR equation (M0, T1). Apparent T1 values from  the MOLLI data  were calculated by 
non-linear least square fitting for three parameters of the LL IR equation (see (16) for 
more details), and the corresponding T1 values were then derived from the apparent T1 





registration in-line on the MRI scanner (Siemens WIP # 448).   
For AIR images, we used an iterative anisotropic diffusion filter to achieve a good 
balance between noise reduction and spatial blurring of source images (34,35). We used 
15 iterations with gradient modulus threshold = 10 for the conventional anisotropic 
diffusion equation described in (34,35). After this pre-processing step, we performed 
rigid body transformation to co-register the PD and T1w images based on a Fourier-based 
algorithm (36). Following these pre-processing steps, we calculated the pixel-by-pixel T1 
maps using Eq. [3.2]. Customized software in MATLAB was used to manually segment 
the regions of interest (ROI) (whole phantom, left ventricular myocardium, blood pool). 
T1 was calculated on a pixel-by-pixel basis and averaged within the ROI.  
For statistical analysis, T1 measurements by MOLLI and AIR were compared using 
the Pearson’s correlation and Bland-Altman analyses. Inter-scan agreements for MOLLI 
and AIR T1 were assessed using the Bland-Altman analysis. 
 
3.2.10 Theoretical noise analysis 
To estimate the T1 error due to noise, we performed a theoretical noise analysis using 
Eq. [3.2] as a function of true T1 ranging from 400 to 1500 ms (5 ms steps). To estimate 
clinically relevant white Gaussian noise, in a 38-years-old male volunteer, we acquired 
one PD image acquisition with full k-space encoding and a noise map using the same 
pulse sequence without RF excitation. The myocardium was segmented manually, and 
the SNR was calculated as the ratio of the mean myocardial signal and standard deviation 
of noise derived from the noise map.  In this subject, PD SNR was 142. Given that our 





105. We further attenuated this value by 25% for a conservative estimate of 79. For 
simplicity, we let PD signal = 79 and added white Gaussian noise with standard deviation 
= 1 (i.e., SNR = 79). For each T1, T1w image signal was calculated as PD signal 
multiplied by the term (1-exp(-TD/T1)). We then added the same white Gaussian noise 
with standard deviation =1 to the T1w signal. Using Eq. 2, T1 with noise was calculated 
with noise added PD and T1w signals. The theoretical noise analysis was repeated 100 
times (i.e., Monte Carlo). The influence of white noise on T1 accuracy was estimated by 
performing linear regression analysis and calculating RMSE (T1 with noise vs. true T1). 
Reported linear regression statistics and RMSE values represent the mean ± standard 
deviation over 100 measurements. 
 
3.3 Results 
3.3.1 Effects of dummy RF pulses on T1 calculation 
Figure 3.4 shows plots of ratio of Mz,T1/Mz,PD with ramp-up pulses and Mz,T1/Mz,PD 
without ramp-up pulses and ratio of T1 estimation with ramp-up pulses and ideal T1 
(without ramp-up pulses) as a function T1. Our theoretical analysis confirms that 30 
dummy ramp-up RF pulses have negligible effects on T1 calculation (< 0.05%; percent 
error for T1 ranging from 429 to 1471 ms). 
  
3.3.2 Phantom studies 
Figure 3.5 shows the MOLLI and AIR T1 maps for the nine phantoms at simulated 
heart rate and rhythm conditions of 60 bpm, 120 bpm, and arrhythmia, as well as the 
corresponding bar charts summarizing the mean T1 measured over 10 repeated 





the reference T1 and T2 values of the phantoms. Compared with the reference T1 
measured by IR-FSE, MOLLI and AIR had NRMSE of 8% and 3%, respectively, at 60 
bpm, 28% and 3%, respectively, at 120 bpm, and 22% and 3%, respectively, at 
arrhythmia. In addition, MOLLI and AIR T1 measurements had maximum CV of 1.6% 
and 1.1%, respectively, at 60 bpm, 5.9% and 0.6%, respectively, at 120 bpm, and 10.2% 
and 0.8%, respectively, at arrhythmia. These results show that AIR yields relatively 
accurate and precise T1 measurements at three different heart rate and rhythm conditions.   
 
3.3.3 In vivo studies 
Figure 3.6 shows non-contrast and post-contrast (15 min) MOLLI and AIR cardiac T1 
maps for a baseline (prior to pacing) dog and a 38-year-old male volunteer. The MOLLI 
T1 maps exhibited consistently lower T1 values than the AIR T1 maps. Table 3.2 
summarizes mean non-contrast blood and myocardium T1 values for goats, dogs, and 
human, as well as their mean heart rates. Compared with non-contrast myocardial T1 
measured by MOLLI (1198 ms), non-contrast myocardial T1 measured by AIR (1501 ms) 
was in better agreement with a previous study which measured T1 of an excised heart 
(1471 ms)  using a rigorous IR pulse sequence with 35 TI values with 2 averages (26). 
Linear regression analysis of MOLLI and AIR T1 values (Figure 3.7) demonstrated a 
strong correlation with a correlation coefficient (r) of 0.99 for combined animal and 
human data (p < 0.01). Results of the Bland-Altman analysis (Table 3.3) show that the T1 
values measured by the MOLLI and AIR methods are in poor agreement (mean 
difference = 162.0 ms, upper 95% limits of agreement = 348.4 ms, lower 95% limits of 





inter-scan repeatability (Table 3.3), the coefficient of repeatability (CR) was 49 ms (5% 
of mean) for MOLLI and 79 ms (7% of mean) for AIR. Slightly larger CR for AIR can be 
attributed to the fact that AIR acquires only two images whereas MOLLI acquires eleven.  
 
3.3.4 Theoretical noise analysis 
For the theoretical noise analysis, mean RMSE was 24.7 ± 2.2 ms, and the calculated 
T1 values with noise were strongly correlated with true T1 values for PD SNR of 79 (see 
Table 3.4).  
 
3.4 Discussion 
This work demonstrates the feasibility of performing rapid cardiac T1 mapping (e.g., 
2-3 heart beats, depending on heart rate) with relatively accurate and precise T1 values 
(Figs 3.5-7, Tables 3.1-3). This rapid approach is conducive for whole heart coverage in a 
clinical setting. Our proposed AIR T1 mapping method has been demonstrated to be 
insensitive to heart rate and rhythm. While not explicitly tested in this study, our 
proposed AIR T1 mapping pulse sequence is inherently insensitive to T2 effects, because 
they cancel out in the ratio of T1w and PD images acquired using centric k-space 
ordering. Our phantom studies showed that AIR yielded more accurate and precise T1 
measurements than MOLLI at three different heart rate and rhythm conditions compared 
with IR-FSE as the reference, suggesting that AIR may be more accurate and precise than 
MOLLI for cardiac T1 mapping.   
While this new pulse sequence may be clinically useful, there are several issues that 





but its maps tended to be noisier than MOLLI T1 maps. This is not surprising, since AIR 
and MOLLI acquire 2 and 11 images, respectively. To compensate for noise, we used an 
anisotropic diffusion filter to minimize the noise in the raw images, without significant 
spatial blurring.  Another approach to increase the SNR of AIR T1 maps is to acquire 
additional T1-weighted images with different TDs, at the expense of increased scan time 
(18,21-23). Second, while the AIR pulse sequence is insensitive to arrhythmia in terms of 
T1 weighting, the underlying cardiac phase captured by the PD and T1w images may be 
mis-registered in arrhythmia. In such situation, the pixel-by-pixel T1 calculation will lead 
to registration errors. One solution to this problem is to perform advanced registration 
methods, such as affine transformation and deformable models. Another solution is to 
repeat the image acquisition since it only takes 2-3 heart beats. If these solutions do not 
work, then one can calculate T1 using mean myocardial signals measured from separate 
cardiac contour segmentation of PD and T1w images (only valid for diffuse myocardial 
fibrosis). Third, some of our b-SSFP images at 3T did contain banding artifacts 
associated with off-resonance. We carefully excluded such regions in our image analysis, 
but more work (e.g., better B0 shimming, higher receiver bandwidth, etc.) is needed to 
produce artifact-free  b-SSFP images at 3T. We note that we routinely generate artifact 
free b-SSFP images at 1.5T (data not shown). Fourth, we prescribed the cutoff heart rate 
(73 bpm) based on the imaging parameters used in this study. For different combinations 
of TD and temporal resolution, different cutoff heart rates will have to be computed. 
Sixth, we did not use an IR spin echo pulse sequence as the gold standard for T1 mapping 
in vitro. Instead, we elected to use IR FSE as the reference to accelerate the pulse 





measurements may contain negligible errors. Seventh, we used an iterative anisotropic 
diffusion filter to achieve a good balance between noise reduction and spatial blurring of 
source images. This may lead to spatial blurring of focal fibrosis. Eighth, our phantoms 
had T2 ranging from 49 to 485 ms. These values are much higher than clinically relevant 
T2 values (e.g., 41 to 47 ms used in the theoretical analysis, Fig. 3.4). However, our AIR 
results are still valid because AIR is inherently insensitive to T2 effects. Ninth, we used 
TD = 600 ms for this study because our clinical application (AF patients without 
myocardial infarction, LGE T1 mapping at 15 min after administration of single dose of 
Gd-BOPTA at 3T) yields LGE T1 ranging from 600-800 ms. In other clinical 
applications, the range of LGE T1 will depend on a variety of factors, including contrast 
agent type, contrast agent dosage, specific delayed imaging time, field strength, and 
underlying structural heart disease. For applications where a wider range of T1 (e.g., 200-
700 ms) is expected, it is necessary to adjust the TD to be equal to the lower end of T1, at 
the expense of SNR for higher end of T1 (see Figure 3.2B). Tenth, MOLLI T1 maps 
reported in this study were generated in-line with motion registration. As such, spatial 
blurring in MOLLI T1 maps is due to both T2 effects and additional spatial filtering 
introduced by image registration. Eleven, we elected to use the original implementation 
of MOLLI with linear k-space ordering, rather than the optimized MOLLI with centric k-
space ordering (37). While the optimized MOLLI with centric k-space ordering may be 
superior to the original MOLLI with linear k-space ordering in terms of T2 blurring, both 
implementations of MOLLI are sensitive to heart rate and rhythm because they are based 







Rapid cardiac T1 mapping can be performed using our proposed AIR pulse sequence 
with high accuracy and precision. This rapid cardiac T1 mapping pulse sequence may be 
clinically useful for assessment of diffuse myocardial fibrosis in patients, particularly in 
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Table 3.1. Manganese chloride phantom concentrations, reference T1 values measured 



























Table 3.2. Non-contrast left ventricular myocardial and blood pool mean T1 values (± 























Table 3.3. Bland-Altman and Pearson correlation analyses results for T1 










Table 3.4. Linear regression statistics (slope, bias, R
2
) and RMSE for the theoretical 
noise analysis repeated 100 times for PD SNR = 79. Using Eq. 2, T1 with noise was 
calculated with noise added PD and T1w signals as a function of true T1 ranging from 
400 to 1500 ms (5 ms steps). R
2










Figure 3.1. Mz curves for SR and IR acquisitions affected by heart rate and rhythm. 
For IR, Mz is sensitive to the prior history of recovery as a function of heart rate and 









Figure 3.2. A) Theoretical Mz curve showing when T1w image is acquired along the 
Mz recovery curve following B1-insensitive T1 weighting. Note that the PD image is 
acquired with the SR pulse turned off. B) Theoretical sensitivity curve illustrates that 









Figure 3.3. AIR pulse sequence ECG triggering schematic with TD = 600 ms, centric 
k-space ordering, and temporal resolution of 217 ms. For heart rates ≤ 73 bpm, PD and 
T1w images are acquired in two consecutive heart beats. For heart rates > 73 bpm, PD 
and T1w images are acquired in three consecutive heart beats. For efficiency, we 
acquire PD images first, to ensure that initial Mz is equal to M0, and T1w images 
second, since initial Mz for the T1w image is determined by the SR pulse and TD only 









Figure 3.4. Plots of ratio of Mz,T1/Mz,PD with ramp-up pulses and Mz,T1/Mz,PD without 
ramp-up pulses and ratio of T1 estimation with ramp-up pulses and ideal T1 (without 
ramp-up pulses) as a function of T1 ranging from 429 to 1471 ms. Our theoretical 
analysis confirms that 30 dummy ramp-up RF pulses have negligible effects on T1 









Figure 3.5. A) The top row shows MOLLI T1 maps at (left column) 60 bpm, (middle 
column) 120 bpm, and  (right column) simulated arrhythmia for phantoms with a 
range of MnCl concentrations. The middle row shows the corresponding AIR T1 maps 
at 60 bpm, 120 bpm, and arrhythmia. B) The corresponding bar charts representing the 









Figure 3.6. Non-contrast and post-contrast MOLLI and AIR cardiac T1 maps for a 
baseline (prior to pacing) dog and a 38-year-old male volunteer. MOLLI T1 maps 









Figure 3.7. (A) Pearson’s correlation and (B) Bland-Altman analyses results for 







VALIDATION OF THE AIR CARDIAC T1 MAPPING PULSE SEQUENCE 
AGAINST HISTOLOGY 
 
This chapter describes a study that was conducted to validate the AIR cardiac T1 
mapping against histology. This work was published in "Post-contrast myocardial T1 and 
ECV disagree in a longitudinal canine study" NMR in Biomedicine 2014, Volume 27, 
Issue 8, Pages 988-995. Reprinted with permission from Wiley Periodicals, Inc. 
 
4.1 Introduction 
Diffuse myocardial fibrosis is a well-established marker of adverse structural 
remodeling in a variety of heart diseases, including: atrial fibrillation (AF)(1), heart 
failure (2), hypertrophic cardiomyopathy (3,4), aortic stenosis (3,4), cardiac amyloidosis 
(3,4), myocardial infarction (4), diabetes (5), and congenital heart disease (6). 
Cardiovascular magnetic resonance (CMR) methods such as post-contrast cardiac T1 
mapping (7-9) and extracellular volume (ECV) mapping (4,9-12), derived from native 
and post-contrast myocardial and blood T1 measurements, are the only validated non-
invasive tests for interstitial fibrosis. The CMR field is recognizing that post-contrast 
myocardial T1 measurement is sensitive to a variety of confounders, including: renal 





delayed imaging time after administration of contrast agent. To account for these 
confounders, many investigators in the CMR field are migrating toward myocardial ECV 
as a marker of diffuse myocardial fibrosis (4,6,10-13). Despite the theoretical advantages 
of ECV over post-contrast myocardial T1 (14), systematic experimental studies 
comparing the two measurements are largely lacking, particularly in a longitudinal 
setting.  
Animal models provide a unique opportunity to perform a longitudinal study to 
monitor the temporal changes in left ventricular (LV) structural remodeling. We have 
established a canine model with chronic AF to study the relationship between AF and 
cardiac pathophysiology (15). We sought to leverage this longitudinal canine study and 




4.2.1 Animal preparation for CMR at 3T 
Seventeen mongrel dogs (12 females, 5 males; mean initial weight = 26 ± 4 kg) with 
different durations of AF induced by rapid atrial pacing (RAP)(15,16) were included in 
this study. These canines with chronic AF were part of a separate longitudinal study 
aimed at characterizing the relationship between AF and cardiac pathophysiology. For 
more details on the pacemaker implantation and other procedures conducted to induce 
AF, see reference (15). In this study, disease duration is defined as the duration since the 
onset of RAP, since this is the starting point at which cardiac physiology is altered. As 





mean RAP = 205.8 ± 187 days) were included in this study, for a total of 46 CMR 
sessions. Canines were fasted for a minimum of 12 hours before MRI. Animals were 
anesthetized with propofol (5-8 mg/kg, IV) for intubation and subsequently ventilated 
and maintained in a surgical plane of anesthesia with 1.5-3% isoflurane. Ventilation was 
controlled using a ventilator (DRE Premier XP MRI-Compatible Veterinary Anesthesia 
Machine, DRE Veterinary, Louisville, KY). Breath-hold MRI acquisition was performed 
with the ventilation suspended. Each animal was electrically cardioverted approximately 
30 min prior to MRI setup. Note that cardiac T1 mapping and cine MRI methods were 
performed at least 1 hour after cardioversion to minimize the effects of myocardial 
stunning. Heart rate, core body temperature, blood pressure, end-tidal CO2, and oxygen 
saturation were continuously monitored and maintained within normal ranges. Blood was 
drawn during the MRI exam for hematocrit calculation. Pacemaker implantation and 
imaging (see below) were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee at the University of Utah. 
 
4.2.2 CMR hardware 
CMR was performed on two 3T whole-body MRI scanners (Tim Trio and Verio, 
Siemens Healthcare, Erlangen, Germany) equipped with a gradient system capable of 
achieving a maximum gradient strength of 45 mT/m and a slew rate of 200 T/m/s. 
Among a total of 46 CMR scans, 32 and 14 scans were conducted on the Verio and Tim 
Trio scanners, respectively. The radio-frequency excitation was performed using the body 
coil. For the experiments conducted on the Tim Trio system, a 6-element body matrix 





reception. For the experiments conducted on the Verio system, a 32-element cardiac coil 
(RAPID MR International, Columbus, OH) was used for signal reception. 
 
4.2.3 CMR protocol  
For cardiac T1 measurements, we used the arrhythmia-insensitive rapid (AIR) cardiac 
T1 mapping pulse sequence (17). Briefly, the AIR cardiac T1 mapping pulse sequence 
acquires two single-shot balanced steady-state of free precession (b-SSFP) images: 1) a 
proton density-weighted image and 2) a T1-weighted image. For more details on the AIR 
cardiac T1 mapping pulse sequence, see reference (17). To minimize the impact of 
variation in contrast agent dosage and specific delayed imaging time, we measured the 
weight of each animal immediately prior to MRI, administered exactly 0.15 mmol/kg of 
gadobenate dimeglumine (Gd-BOPTA)(MultiHance, Bracco Diagnostics Inc., Princeton, 
NJ), and performed cardiac T1 mapping pre-contrast and at exactly 15 min following Gd-
BOPTA administration. We assumed that 15 min after bolus injection of Gd-BOPTA is 
equilibrium (4,18).  
The AIR cardiac T1 mapping pulse sequence was performed with the following 
imaging parameters: field of view = 260 mm × 195 mm, slice thickness = 8 mm, image 
acquisition matrix = 192 × 144, generalized autocalibrating partially parallel acquisitions 
(GRAPPA)(19) acceleration factor 1.8, flip angle = 35º, saturation-recovery time delay 
(TD) = 600 ms, receiver bandwidth = 930 Hz/pixel, and temporal resolution = 217 ms. In 
this study, we also used "paired" consecutive phase-encoding steps in centric k-space 
ordering to minimize b-SSFP image artifacts due to eddy currents (20). We acquired 3 





beats (depending on heart rate). Using cardiac long-axis views as guides, for each CMR 
session, we defined the mid-ventricular short-axis plane as the mid-point between the 
mitral valve plane and apical cap, the basal short-axis plane as the mid-point between the 
mid-ventricular plane and mitral valve plane, and the apical short-axis plane as the mid-
point between the mid-ventricular plane and apical cap.  
As a secondary analysis, we also quantified LV functional parameters from 
retrospective ECG-gated breath-hold cine MR data acquired with b-SSFP readout 
(21,22). We imaged the whole heart with a stack of short-axis planes with the following 
imaging parameters: field of view = 260 mm × 195 mm, image acquisition matrix = 192 
× 144, GRAPPA parallel imaging acceleration factor = 1.8, slice thickness = 7 mm, flip 
angle = 40-45º, receiver bandwidth = 1000 Hz/pixel, echo time (TE) = 1.3 ms, repetition 
time (TR) = 3 ms, 12-14 short-axis slices (with zero gap), spatial resolution = 1.4 mm × 
1.4 mm, number of k-space lines per cardiac phase = 7, temporal resolution = 21 ms, and 
reconstructed cardiac frames = 25. 
 
4.2.4 CMR image analysis 
For cardiac T1 quantification, we calculated the pixel-by-pixel T1 map by dividing the 
T1-weighted image, IT1W, by the proton-density-weighted image, IPD, to correct for the 
unknown equilibrium magnetization, M0, and then solving the Bloch equation governing 
T1 relaxation describing the ideal saturation-recovery experiment (17): 
    
   
 
      
       
  
             
   
   
     
    







Customized software in MATLAB was used to manually segment the myocardial 
contours and LV blood pool for each image (i.e., independent contour tracings for native 
and post-contrast T1 maps per imaging plane per animal per CMR session). Care was 
taken to avoid partial volume averaging for each contour tracing. AIR cardiac T1 data 
were randomized for analysis by the first reader (KH), who was blinded to the cine MR 
and histology results. Myocardial and blood T1s were averaged within their respective 
contours for each of three LV locations (base, mid, apex). Myocardial ECV was 
calculated according to (13):                                 , where     
is      of myocardium, and      is      of blood, and  is the difference between post-
contrast and native. 
For cardiac functional assessment, short-axis cine MR images were analyzed using 
Argus software (Siemens Healthcare, Erlangen, Germany). Another reader (MK), who 
was blinded to the T1 and histology results, manually segmented the endocardial and 
epicardial LV contours in end-diastole and end-systole to calculate the following LV 
functional parameters: end diastolic volume (EDV), end systolic volume (ESV), stroke 
volume (SV), LV ejection fraction (LVEF), and LV mass. We note that papillary muscle 
was excluded for volume measurements, whereas it was included for mass measurement. 
The interventricular septum was included as part of the LV, while the left ventricular 
outflow tract was excluded.  
 
4.2.5 Histological analysis 
Six canines enrolled in this study were terminated at their scheduled disease duration 





specimens (approximately 1 cm × 1 cm × 1 cm in size) were extracted from mid-ventricle 
of the antero-lateral LV wall of excised hearts fixed in 10% buffered formalin. Tissues 
were processed according to standard pathology protocol (i.e., tissues fixed in formalin, 
embedded in paraffin blocks, and sectioned at 4-6 μm). On average, a total of 6-10 
sections were prepared with Masson’s Trichrome stain to quantify collagen volume 
fraction (CVF). In a consensus fashion, light-microscopic examination was performed by 
two experienced pathologists (ECH, RL), who were blinded to animal history, disease 
duration, and CMR results. The optimal histologic areas were identified visually by 
consensus, and the resulting digital images were captured using Infinity 2 microscope 
digital camera (Lumenera, Ottawa, Ontario, Canada) at 100× magnification. Each digital 
image was evaluated for CVF quantification using customized segmentation software. 
This software requires user input to learn the patterns, intensity, and color for inclusion 
(myocytes and interstitial fibrosis) and exclusion (red blood cells, blood vessels, and 
adipose tissue) elements. We used several training slides of LV tissues with Masson’s 
Trichrome stain to establish the inclusion and exclusion classification criteria. After 
training, the software generates automatically a classification mask by detecting fibrosis 
and myocyte pixels based on the trained inclusion and exclusion classification criteria. 
The two pathologists then compared the resulting classification mask to the original 
digital Trichrome image, in order to visually confirm the accuracy of the software in 
identifying the appropriate elements. Finally, using the resulting classification mask (see 







4.2.6 Statistical analysis 
For statistical analysis of temporal changes in CMR parameters, we examined the 
association between the repeated measurements of these parameters and disease duration 
using a linear-mixed-effect model (LMEM)(23) (N = 46). The exchangeable correlation 
structure was used to specify the correlation structure among the repeated measurements 
within each animal. This longitudinal study has an unbalanced distribution of repeated 
measurements for the different animals. We resolved this issue with LMEM, where the 
repeated measurements within each animal are treated as a cluster of observations. All 
LMEMs were fitted with the random intercept for each animal and disease duration as the 
fixed effect, where p-value < 0.05 was considered significant. Individual trajectories of 
CMR parameters were plotted over disease duration. For the temporal change analysis, 
myocardial and blood T1 values were averaged over the basal and mid-ventricular short-
axis planes. Apical short-axis plane results were excluded for the temporal change 
analysis, because they may be susceptible to partial volume averaging effects. We note 
that animals with only one data point (dogs 5, 9, 11, 13, 14, 16, 17) were excluded for the 
temporal change analysis (but included for other analyses). 
For statistical analysis of post-mortem LV tissues, we examined the association 
between histologic quantification of CVF and disease duration using linear regression (N 
= 6), where p-value < 0.05 was considered significant. 
We also performed the following secondary analyses. To investigate whether there 
are regional differences in T1 measurements between 3 different short-axis planes, we 
performed analysis of variance (ANOVA) for native myocardial T1, native blood T1, 





whether the two different 3T MRI scanners produce different T1 results, we performed a 
two-sample t-test (two-tailed) for native myocardial and blood T1 measurements only, 
since the native T1 measurements did not change significantly over disease duration and 
allows a comparison across different animals (see Table 4.2). To investigate whether 
electrical cardioversion induces myocardial edema, in 5 animals, we performed native T1 
mapping before and 1 hour after cardioversion and compared their native T1 
measurements. A paired t-test (two-tailed) was used to compare native myocardial T1 




Figure 4.1 shows representative cardiac T1 maps in three short-axis planes of a dog at 
464 days since the onset of RAP, illustrating good data and contour tracing quality used 
in this study. Figure 4.2 shows post-mortem LV specimens of two different dogs with 
Masson's trichrome staining at baseline and 22 months after the onset of RAP, as well as 
their corresponding classification masks used to quantify CVF. These LV specimens and 
classification masks illustrate good data quality used in this study. 
In 17 animals observed over disease duration ranging from 0-22 months (mean RAP 
= 205.8 ± 187 days), post-contrast myocardial T1 decreased significantly from 872 to 698 
ms (Fig. 4.3; p < 0.001), which corresponds to a 24.9% relative reduction. In contrast, 
ECV increased from 21.0 to 22.0% (p = 0.38), which corresponds to only a 4.5% relative 
increase. This discrepancy was partially investigated by histologic analysis of post-





from 0-22 months, CVF quantified by histology increased from 0.9 to 1.9% (Fig. 4.3; 
slope = 0.044, bias = 1.2%, correlation coefficient = 0.30; p = 0.56), which agreed more 
with ECV than post-contrast myocardial T1.  
We examined other parameters to identify the cause for this discrepancy. Among 
cardiac T1 data (native myocardial T1, native blood T1, post-contrast blood T1), only post-
contrast blood T1 decreased significantly from 578 to 402 ms (Fig. 4.3; p < 0.001), which 
corresponds to a 43.8% relative reduction. Note that the temporal trends in post-contrast 
myocardial and blood T1s are similar. Both native myocardial T1 and native blood T1 did 
not change significantly (Table 4.2). Among LV functional parameters (EDV, ESV, SV, 
LVEF, and LV mass), only LVEF decreased significantly from 46.1 to 33.6% (p = 0.02; 
Table 4.2), which corresponds to a 37.2% relative reduction, suggesting progressively 
worsening LV dysfunction.  
The results from the secondary analyses (regional variations in T1, inter-scanner 
variability of native T1, comparison of native myocardial T1 between pre and post-
cardioversion) were as follows. In all animals, the mean native cardiac T1, native blood 
T1, post-contrast cardiac T1, and post-contrast blood T1 values were not different between 
basal, mid-ventricular, and apical short-axis planes (see Table 4.3 for the statistics). 
According to a two-sample t-test (two-tailed), only mid-ventricular and basal myocardial 
T1 measurements were significantly different between two different 3T MRI scanners (p 
< 0.05; see Table 4.4), but note that the magnitude of the percent change was less than 
4% for each parameter (i.e., negligible). In 5 animals, the mean native myocardial T1 
before (1374 ± 34 ms) and 1 hour after cardioversion (1399 ± 27 ms) was not different (p 






In this study, in canine models with chronic AF (0 - 22 months), we measured the 
temporal changes in post-contrast myocardial T1 and myocardial ECV, both of which 
have been associated with interstitial fibrosis (4,7-12). In the observed canines, post-
contrast myocardial T1 decreased significantly over disease duration, whereas myocardial 
ECV did not. Histologic quantification of CVF in a subset of animals suggests a non-
significant difference in CVF over disease duration, which agrees more with ECV than 
post-contrast myocardial T1. We note that a more comprehensive study, including 
histologic, cardiac, and renal functional analyses, is warranted to test rigorously which 
CMR parameter (ECV or post-contrast myocardial T1) agrees more with CVF. 
Interestingly, post-contrast blood T1 decreased significantly over disease duration, 
suggesting that decreasing post-contrast myocardial T1 may have been largely driven by 
decreasing post-contrast blood T1. This observational study is the first report of 
conflicting findings between post-contrast myocardial T1 and ECV in the context of a 
longitudinal study. The results of this study agrees with a prior cross-sectional study (9), 
which first reported a weak association between post-contrast myocardial T1 and ECV in 
a sub-analysis.  
This study also highlights the benefits of myocardial ECV over post-contrast 
myocardial T1. In the 17 animals studied over disease duration ranging from 0-22 months 
with an identical AIR cardiac T1 mapping protocol (MRI at exactly 15 min after 
administration of 0.15 mmol/kg of MultiHance), we observed decreasing trends in post-
contrast myocardial T1 and post-contrast blood T1. These temporal trends suggest that 





contrast blood T1. Our cine MRI data showed that LVEF decreased significantly with 
disease duration, and it is plausible that a reduced cardiac output could lead to higher 
concentration of contrast agent in the blood at 15 min after administration (i.e., since less 
blood is delivered to the kidney per unit time). We note that the separate longitudinal 
study design did not anticipate renal function to be influenced by chronic AF. 
Unfortunately, due to the nature of this study (retrospective analysis of data collected 
from a separate longitudinal study), we are unable to measure changes in renal function 
over disease duration. Consequently, we are unable to draw a conclusion on what caused 
the decreasing trend in post-contrast blood T1 over disease duration. Despite the lack of 
renal functional data and limited histologic data, our study suggests that CVF agrees 
better with ECV than post-contrast myocardial T1.  
It should be noted that canine T1 measurements reported in this pre-clinical study may 
not be translatable to other pre-clinical studies using different CMR protocols. A variety 
of factors, such as field strength, contrast agent type and dosage, specific delayed 
imaging time, pulse sequence type, heart rate and rhythm, may influence the accuracy of 
T1 measurements. Therefore, CMR researchers must be careful when translating T1 
values presented in this preclinical study into their own studies.  
 
4.5 Study Limitations 
A limitation of this study is that the enrolled canines were part of a separate 
longitudinal study. Consequently, our animal data had an unbalanced distribution of 
repeated measurements (see Table 4.1). We used LMEM to account for the unbalanced 





histologic analysis was performed for only 6 animals (N=6), which were sacrificed 
according to the study objectives of the separate longitudinal study. In addition, for each 
animal, we analyzed a post-mortem tissue specimen of approximately 1 cm × 1 cm × 1 
cm in size from the mid-ventricle of the antero-lateral LV wall to represent the whole LV. 
While it would be more comprehensive to analyze tissues from multiple locations of the 
LV, this study did not have access to the rest of the heart. A more comprehensive 
histological evaluation (e.g., biopsy over disease duration) is warranted to confirm our 
CMR findings. However, we note that performing longitudinal biopsies would add 
considerable expense and procedural risk to the separate longitudinal study. Furthermore, 
biopsy samples of the right ventricular septum are small in size (~1-2 mm in length), 
thereby harder to process and sensitive to sampling errors. Another potential confounder 
is heart-rate variation in animals under anesthesia during MRI. We typically maintain a 
steady level of isoflurane during MRI, but the animals' heart rate varies within and across 
MRI sessions. Consequently, cardiac functional parameters may have been affected by 
variations in heart rate. Although we performed cine CMR at least one hour after 
cardioversion, cardiac functional parameters reported in this study may have been 
influenced by residual myocardial stunning.  
 
4.6 Conclusions 
This study shows that post-contrast myocardial T1 and ECV may disagree in a 
longitudinal canine study. A more comprehensive study, including histologic, cardiac, 
and renal functional analyses, is warranted to test rigorously which CMR parameter 






1. Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL, Kalman JM, Kaye 
DM, Taylor AJ. Diffuse ventricular fibrosis in atrial fibrillation: noninvasive 
evaluation and relationships with aging and systolic dysfunction. J Am Coll 
Cardiol 2012;60(23):2402-2408. 
 
2. de Leeuw N, Ruiter DJ, Balk AH, de Jonge N, Melchers WJ, Galama JM. 
Histopathologic findings in explanted heart tissue from patients with end-stage 
idiopathic dilated cardiomyopathy. Transplant International 2001;14(5):299-306. 
 
3. Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, 
Piechnik SK, Neubauer S, Roberts N, Moon JC. Comparison of T1 mapping 
techniques for ECV quantification. Histological validation and reproducibility of 
ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J 
Cardiovasc Magn Reson 2012;14:88. 
 
4. White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, 
Piechnik SK, Robson MD, Hausenloy DJ, Sheikh AM, Hawkins PN, Moon JC. 
T1 mapping for myocardial extracellular volume measurement by CMR: bolus 
only versus primed infusion technique. JACC Cardiovascular Imaging 
2013;6(9):955-962. 
 
5. Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, 
Mulukutla SR, Simon MA, Shroff SG, Kuller LH, Schelbert EB. Myocardial 
extracellular volume fraction quantified by cardiovascular magnetic resonance is 
increased in diabetes and associated with mortality and incident heart failure 
admission. European Heart Journal 2013. 
 
6. Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M. Quantification of 
diffuse myocardial fibrosis and its association with myocardial dysfunction in 
congenital heart disease. Circ Cardiovasc Imaging 2010;3(6):727-734. 
 
7. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, 
Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac 
magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 
2008;52(19):1574-1580. 
 
8. Sibley CT, Noureldin RA, Gai N, Nacif MS, Liu S, Turkbey EB, Mudd JO, van 
der Geest RJ, Lima JA, Halushka MK, Bluemke DA. T1 mapping in 
cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. 
Radiology 2012;265(3):724-732. 
 
9. Miller CA, Naish JH, Bishop P, Coutts G, Clark D, Zhao S, Ray SG, Yonan N, 
Williams SG, Flett AS, Moon JC, Greiser A, Parker GJ, Schmitt M. 





the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging 
2013;6(3):373-383. 
 
10. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, 
McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance 
for the measurement of diffuse myocardial fibrosis: preliminary validation in 
humans. Circulation 2010;122(2):138-144. 
 
11. Kehr E, Sono M, Chugh SS, Jerosch-Herold M. Gadolinium-enhanced magnetic 
resonance imaging for detection and quantification of fibrosis in human 
myocardium in vitro. Int J Cardiovasc Imaging 2008;24(1):61-68. 
 
12. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, 
Alharethi R, Li D, Hershberger RE. Cardiac magnetic resonance imaging of 
myocardial contrast uptake and blood flow in patients affected with idiopathic or 
familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 
2008;295(3):H1234-H1242. 
 
13. Arheden H, Saeed M, Higgins CB, Gao DW, Bremerich J, Wyttenbach R, Dae 
MW, Wendland MF. Measurement of the distribution volume of gadopentetate 
dimeglumine at echo-planar MR imaging to quantify myocardial infarction: 
comparison with 99mTc-DTPA autoradiography in rats. Radiology 
1999;211(3):698-708. 
 
14. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, 
Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert 
EB. Myocardial T1 mapping and extracellular volume quantification: a Society 
for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of 
the European Society of Cardiology consensus statement. J Cardiovasc Magn 
Reson 2013;15:92. 
 
15. Dosdall DJ, Ranjan R, Higuchi K, Kholmovski EG, Angel N, Li L, Macleod R, 
Norlund L, Olsen A, Davies CJ, Marrouche NF. Chronic atrial fibrillation causes 
left ventricular dysfunction in dogs but not goats: experience with dogs, goats, 
and pigs. Am J Physiol Heart Circ Physiol 2013. 
 
16. Nishida K, Michael G, Dobrev D, Nattel S. Animal models for atrial fibrillation: 
clinical insights and scientific opportunities. Europace 2010;12(2):160-172. 
 
17. Fitts M, Breton E, Kholmovski E, Dosdall D, Vijayakumar S, Hong K, Ranjan R, 
Marrouche N, Axel L, Kim D. Arrythmia insensitive rapid cardiac T1 mapping 
pulse sequence. Magn Reson Med 2013;70:1274-1282. 
 
18. Schelbert EB, Testa SM, Meier CG, Ceyrolles WJ, Levenson JE, Blair AJ, 
Kellman P, Jones BL, Ludwig DR, Schwartzman D, Shroff SG, Wong TC. 





gadolinium cardiovascular magnetic resonance in humans: slow infusion versus 
bolus. J Cardiovasc Magn Reson 2011;13:16. 
 
19. Griswold MA, Jakob PM, Heidemann RM, Nittka M, Jellus V, Wang J, Kiefer B, 
Haase A. Generalized autocalibrating partially parallel acquisitions (GRAPPA). 
Magn Reson Med 2002;47(6):1202-1210. 
 
20. Bieri O, Markl M, Scheffler K. Analysis and compensation of eddy currents in 
balanced SSFP. Magn Reson Med 2005;54(1):129-137. 
 
21. Carr JC, Simonetti O, Bundy J, Li D, Pereles S, Finn JP. Cine MR angiography of 
the heart with segmented true fast imaging with steady-state precession. 
Radiology 2001;219(3):828-834. 
 
22. Barkhausen J, Goyen M, Ruhm SG, Eggebrecht H, Debatin JF, Ladd ME. 
Assessment of ventricular function with single breath-hold real-time steady-state 
free precession cine MR imaging. AJR Am J Roentgenol 2002;178(3):731-735. 
 
23. Diggle P, Diggle P. Analysis of longitudinal data. Oxford ; New York: Oxford 





























Table 4.1. Summary of animal gender, initial weight, and MRI date with respect to 




















Table 4.2. LMEM statistics to estimate the temporal changes of CMR parameters. We 
note that the T1 and ECV measurements are averaged over the basal and mid-
ventricular short-axis planes. CI: confidence interval; SE: standard error. Mean RAP = 
205.8 ± 187 days. For graphical displays of these parameters, see Figure 4.3. Percent 

















Table 4.3. Comparison of mean native myocardial T1, native blood T1, post-contrast 
myocardial T1, and post-contrast blood T1 values for the basal, mid-ventricular, and 
apical short-axis planes. According to ANOVA, all four T1 measurements were not 




















Table 4.4. Comparison of mean native myocardial and blood T1 values across two 
different 3T MRI scanners. According to a two-sample t-test (two-tailed), only mid-
ventricular and basal myocardial T1 measurements were significantly different (p < 
0.05), but note that the magnitude of the percent change was less than 4% for each 





















Figure 4.1. Representative post-contrast cardiac T1 maps (top row) and the same maps 
with contour tracings (bottom row), illustrating good data and contour tracing quality 
















Figure 4.2. Post-mortem LV samples with Masson's trichrome stain (top row) and the 
resulting classification masks (bottom row) used to calculate CVF: RAP = 0  (left) and 
RAP = 22 months (right). All specimens displayed with 10× magnification. Red: 
myocyte; blue: interstitial fibrosis; white: interstitium (and additional artificial space 








Figure 4.3. Plots of the estimated regression line (solid line), along with the 95% 
confidence intervals (dashed lines), describing the temporal changes in the following 
parameters: native myocardial T1 (a), native blood T1 (b), post-contrast myocardial T1 
(c), post-contrast blood T1 (d), ECV (e), and histologic quantification of CVF (f), 







COMPARISON OF AIR AND MOLLI CARDIAC T1 MAPPING  
PULSE SEQUENCES 
 
This chapter describes systematic differences between AIR and MOLLI cardiac T1 
mapping pulse sequences. This work was published in "MOLLI and AIR T1 mapping 
pulse sequences yield different myocardial T1 and ECV measurements" NMR in 
Biomedicine 2014, Volume 27, Issue 11, Pages 1419-1426. Reprinted with permission 
from Wiley Periodicals, Inc. 
 
5.1 Introduction 
Diffuse myocardial fibrosis is a marker of adverse structural remodeling in a variety 
of heart diseases. While myocardial biopsy is the current gold standard for assessment of 
diffuse cardiac fibrosis, it is rarely clinically indicated due to its associated non-negligible 
risk of complications and sensitivity to sampling errors. Cardiovascular magnetic 
resonance (CMR) is the only proven non-invasive modality for quantifying diffuse 
myocardial fibrosis. Both post-contrast myocardial T1 (1-4) and myocardial extracellular 
volume (ECV) fraction (4-8), derived from native and post-contrast myocardial and blood 
T1 measurements, have been associated with diffuse interstitial fibrosis burden. These 





invasive myocardial biopsy with CMR (9).  
Among several different cardiac T1 mapping pulse sequences reported in literature 
(10-19), modified Look-Locker Inversion-recovery (MOLLI)(10) is the most widely used 
and commercially available as a work-in-progress. While MOLLI has been an important 
development in CMR, it requires a long scan time (17 heart beats) and is known to be 
sensitive to rapid heart rate and arrhythmia (20,21), T2 and magnetization transfer effects 
(19), and inversion pulse efficiency (22,23). These limitations are particularly concerning 
for imaging patients with irregular heart rhythm and/or rapid rates (e.g., atrial 
fibrillation). In response, we developed an arrhythmia-insensitive-rapid (AIR) cardiac T1 
mapping pulse sequence (15) based on transmit radio-frequency field (B1+)-insensitive 
saturation-recovery of magnetization preparation (24), in order to enable accurate cardiac 
T1 mapping in patients with rapid heart rate and/or arrhythmia. Because AIR cardiac T1 
mapping is relatively new, reports of its performance are limited to a few preliminary 
studies (15,25-27).      
Recently, the CMR field is recognizing that post-contrast myocardial T1 is sensitive 
to confounders such as renal function, hematocrit, magnetic field strength, contrast agent 
type and dosage, and specific delayed imaging time after administration of contrast agent. 
Hence, the CMR field is migrating towards ECV, because it is largely insensitive to such 
confounders. Several recent studies using MOLLI have reported ECV cutoff values to 
distinguish between normal and diseased myocardium (4,28-30). It is unclear if these 
cutoff values are translatable to different T1 mapping pulse sequences such as AIR and 
others. This is especially important since other studies have reported that inversion-





than saturation-recovery based T1 mapping pulse sequences (31). As an important step 
towards clinical and pre-clinical utility of AIR, it is necessary to determine whether AIR 
and MOLLI yield comparable myocardial ECV (i.e., determine if ECV cutoff values 
established by MOLLI are translatable to AIR). The purpose of this study was to 
evaluate, in well-controlled canine and pig experiments, the relative accuracy and 
precision, as well as intra- and inter-observer variability in data analysis, of ECV 
measured with AIR as compared with MOLLI. 
 
5.2 Methods 
5.2.1 MRI hardware 
CMR was performed on two 3T whole-body MRI scanners (Verio and Tim Trio, 
Siemens Healthcare, Erlangen, Germany), each equipped with a gradient system capable 
of achieving a maximum gradient strength of 45 mT/m and a slew rate of 200 T/m/s. The 
radio-frequency excitation was performed using the body coil. The pig experiments were 
performed on the Tim Trio MRI scanner with standard receiver coil arrays (typically 12-
elements total). Canine experiments were performed on the Verio MRI scanner with a 32-
element cardiac coil array (RAPID MR International, Columbus, OH). 
 
5.2.2 Pulse sequence 
We used the MOLLI (Siemens WIP # 448) and AIR cardiac T1 mapping pulse 
sequences with balanced steady-state of free precession (b-SSFP) readout and the 
following identical set of imaging parameters: field of view = 280 mm × 210 mm (phase-





1.5 mm × 1.5 mm, slice thickness = 8 mm, generalized autocalibrating partially parallel 
acquisitions (GRAPPA)(32) acceleration factor 1.8, TR = 2.7 ms, TE = 1.1 ms, flip angle 
= 35º, receiver bandwidth = 930 Hz/pixel, saturation-recovery time delay (TD) = 600 ms, 
and temporal resolution  = 217 ms.  
Figure 5.1 shows pulse sequence diagrams of AIR and MOLLI. Briefly, AIR acquires 
one proton-density weighted image and one T1 weighted image with breath-hold duration 
= 2-3 heart beats (depending on heart rate). MOLLI acquires 11 T1 weighted images 
following three inversion pulse modules (3-3-5, as shown). In this study, for AIR, we 
used "paired" consecutive phase-encoding steps in centric k-space ordering to minimize 
b-SSFP artifacts arising from eddy currents (33). For MOLLI with breath-hold duration  
= 17 heart beats, we used the inversion times (i.e., 3-3-5) and flip angle of 35 as 
previously described (34). 
 
5.2.3 Animal subjects 
Animal MRI was performed in accordance with protocols approved by our 
Institutional Animal Care and Use Committee. We note that this CMR study was added 
onto separate canine and pig CMR experiments, and that cardiac tissues were not made 
available for histolic analysis. We note that pig experiments were conducted after the 
canine experiments were completed, in order to acquire additional data for analysis of 
precision (i.e., since repeated measurements were not made in canines). For both canine 
and pig experiments, animals were anesthetized with propofol (5-8 mg/kg, IV) for 
intubation and subsequently ventilated and maintained in a surgical plane of anesthesia 





MRI-Compatible Veterinary Anesthesia Machine, DRE Veterinary, Louisville, KY). 
Breath-hold CMR image acquisitions were performed at end-expiration with the 
respirator suspended. Heart rate, core body temperature, blood pressure, end-tidal CO2, 
and oxygen saturation were continuously monitored and maintained within normal 
ranges. Blood was drawn during the CMR exam for hematocrit calculation. 
 
5.2.4 Experiment 1: Evaluation of relative accuracy in canines 
We imaged 16 mongrel dogs with normal myocardium (8 males and 8 females; 29.9 
± 4.2 kg) to assess the agreement of myocardial T1 and ECV measurements between 
MOLLI and AIR. In each dog, we performed native cardiac T1 mapping and post-contrast 
cardiac T1 mapping in a mid-ventricular short-axis plane during steady-state equilibrium 
of gadobenate dimeglumine (Gd-BOPTA)(Multihance, Bracco Diagnostics Inc., 
Princeton, NJ; ~45 min after slow infusion at 0.002 mmol/kg/min). This slow infusion 
rate was determined empirically based on our extensive experience with large animal 
(dogs, goats, pigs) CMR experiments. Note that steady-state equilibrium ensures identical 
concentration of Gd-BOPTA throughout repeated MRI measurements and allows for a 
fair comparison of post-contrast myocardial and blood T1 measurements by two different 
pulse sequences. Furthermore, by performing CMR during equilibrium, the specific pulse 
sequence order was irrelevant.  
 
5.2.5 Experiment 2: Evaluation of relative precision in pigs 
Following the completion of separate canine experiments, we conducted an additional 





imaged 6 female pigs (mean weight = 50 ± 1.4 kg) with normal myocardium to assess 
scan-to-scan repeatability of MOLLI and AIR. Similar to the canine experiment, in each 
pig, we performed native cardiac T1 mapping and post-contrast cardiac T1 mapping in a 
mid-ventricular short-axis plane during steady-state equilibrium of Gd-BOPTA. MOLLI 
and AIR T1 mapping acquisitions were repeated to quantify scan-to-scan repeatability.  
 
5.2.6 Image analysis 
MOLLI T1 maps were generated in-line on the MRI scanner (Siemens WIP # 448). 
AIR T1 maps were generated off-line as described in reference (15). Customized software 
in MATLAB (R2009a, MathWorks, Inc., Natick, MA) was used to manually segment the 
myocardial contours and blood pools in the left ventricle for each data set separately. 
Care was taken to avoid partial volume averaging for each contour tracing. T1 was 
calculated for AIR (15) and MOLLI (10) according to their corresponding equation. 
Myocardial and blood T1 values were averaged within their respective region of interest. 
Myocardial ECV was calculated as (35):  
                                         
where     is      of myocardium, and      is      of blood, and  is the difference 
between post-contrast and native.  
To assess the impact of data quality on analysis, we assessed intra- and inter-observer 
variability in calculation of T1 and ECV (canine data only). For assessment of intra-
observer variability, one observer (K.H) repeated the image analysis, with at least two 





the second observer (D.K) independently analyzed the data. The two observers were 
blinded to each other, pulse sequence type, and animal identity. 
 
5.2.7 Statistical analysis 
For canine data, we performed a pair-wise t-test to compare T1 and ECV between 
MOLLI and AIR. We also performed linear regression, concordance correlation (which 
accounts for the intercept or additive bias), and Bland-Altman analyses on cardiac T1 and 
ECV measurements to assess correlation and agreement between MOLLI and AIR data. 
For assessment of intra- and inter-observer variability, the Bland-Altman analysis was 
performed on T1 and ECV measurements. A p-value < 0.05 was considered statistically 
significant.  
For pig data, we performed Bland-Altman analysis on myocardial T1 and ECV to 
calculate the coefficient of repeatability (CR), which is defined as 1.95 × standard 
deviation of the difference. To avoid confusion with terminology, we note that CR 
increases with variability in repeated measurements (i.e., lower agreement). All statistical 




5.3.1 Experiment 1: Evaluation of relative accuracy in canines 
Figure 5.2 shows representative native and post-contrast MOLLI and AIR cardiac T1 
maps of one dog, illustrating typical image quality with both acquisitions. As expected, 





(SNR) than AIR T1 maps derived from only 2 images. In this dog (heart rate = 95 bpm), 
MOLLI and AIR cardiac T1 mapping pulse sequences yielded different T1 and ECV 
values (see Figure 5.2 caption for more details).  
In 16 dogs (mean heart rate = 98.8 ± 17.5 bpm; mean hematocrit = 0.42 ± 0.02), as 
expected, mean T1 was significantly different (p < 0.001) between MOLLI (891 ± 373 
ms) and AIR (1071 ± 503 ms), but, surprisingly, mean ECV between MOLLI (21.8 ± 2.1 
%) and AIR (19.6 ± 2.4%) was also significantly different (p < 0.001). Pair-wise t-test 
revealed significant differences for all pairs (p < 0.0001), except for post-contrast blood 
T1 (p = 0.55; Table 5.1). Figure 5.3 shows scatter plots representing the linear regression 
and Bland-Altman analyses on T1 and ECV between MOLLI and AIR acquisitions. 
According to the linear regression and concordance correlation analyses, T1 values were 
strongly correlated (Pearson's correlation coefficient = 0.99, slope = 1.33, bias = -117.6 
ms, p < 0.0001; concordance correlation coefficient = 0.87). According to the Bland-
Altman analysis, the mean difference in T1 was 179 ms (± 95% confidential interval (CI) 
= 468/-109 ms), which corresponds to 18% of the mean T1 value (981 ms). According to 
the linear regression analysis, ECV values were moderately correlated (Pearson's 
correlation coefficient = 0.65, slope = 0.77, bias = 2.8%, p < 0.001). According to the 
concordance correlation analysis, ECV values were weakly correlated (correlation 
coefficient = 0.43). According to the Bland-Altman analysis, the mean difference in ECV 
was -2.2% (± 95% CI = 1.5/-5.9%), which corresponds to 10.8% of the mean ECV value 







5.3.2 Experiment 2: Evaluation of relative precision in pigs 
Consistent with canine data, in 6 pigs (mean heart rate = 78.1 ± 12.1 bpm; mean 
hematocrit = 0.30 ± 0.04), mean T1 was significantly different (p < 0.01) between 
MOLLI (899.0 ± 462.8 ms) and AIR (1051.2 ± 635.0 ms), and mean ECV was 
significantly different also (p < 0.05) between MOLLI (25.6 ± 3.1%) and AIR (20.7 ± 
1.6%). CR of T1 was considerably lower for MOLLI (32.5 ms) than AIR (82.3 ms), and 
CR of ECV was also lower for MOLLI (1.8%) than AIR (4.5%). Recall that, according to 
the Bland-Altman analysis, lower CR means lower variability (i.e., higher agreement).   
 
5.3.3 Evaluation of intra- and inter-observer variability in analysis  
For T1 calculations (Figure 5.4), the intra-observer agreements for MOLLI and AIR 
data sets were 0.6 ms (upper/lower 95% limits of agreement = 5.3/-4.0 ms) and 0.4 ms 
(upper/lower 95% limits of agreement = 9.2/-8.5 ms), respectively. These correspond to 
CR of 4.7 and 8.8 ms for MOLLI and AIR, respectively. The corresponding inter-
observer agreements for T1 derived from MOLLI and AIR data sets were 0.009 ms 
(upper/lower 95% limits of agreement = 9.8/-9.8 ms) and 0.4 ms (upper/lower 95% limits 
of agreement = 22.7/-21.9 ms), respectively. These correspond to CR of 9.8 and 22.3 ms 
for MOLLI and AIR, respectively.  
For ECV calculations (Figure 5.5), the intra-observer agreements for MOLLI and 
AIR data sets were -0.09% (upper/lower 95% limits of agreement = 0.5/-0.7%) and 
0.02% (upper/lower 95% limits of agreement = 0.5/-0.4%), respectively. These 
correspond to CR of 0.6 and 0.5% for MOLLI and AIR, respectively. The corresponding 





(upper/lower 95% limits of agreement = 1.1/-1.6%) and -0.1% (upper/lower 95% limits 
of agreement = 1.4/-1.6%), respectively. These correspond to CR of 1.3 and 1.5% for 
MOLLI and AIR, respectively. 
 
5.4 Discussion 
In this study, we evaluated, in well-controlled canine and pig experiments, the 
relative accuracy and precision, as well as intra- and inter-observer variability in data 
analysis, of T1 and ECV measured with AIR as compared with MOLLI. Canine 
experiments showed that MOLLI and AIR yield significantly different T1 and ECV 
values (p < 0.001), which have important implications (see below). Both intra- and inter-
observer agreements in T1 calculations were higher for MOLLI than AIR, owing to the 
fact that MOLLI acquires 9 more images than AIR. Interestingly, both intra- and inter-
observer agreements in ECV calculations were similar between MOLLI and AIR, 
possibly owing to off-setting errors when calculating ECV from multiple measurements 
(native and post-contrast myocardial and blood T1s). Pig experiments showed that 
MOLLI yields higher precision than AIR, which was expected since AIR acquires 9 less 
images than MOLLI.  
Our observation has important implications for the CMR community. Currently, there 
are several different variants of inversion-recovery (10,11) and saturation-recovery (12-
14,16) based cardiac T1 mapping pulse sequences, as well as a hybrid inversion- and 
saturation-recovery cardiac T1 mapping pulse sequence (17) and the “TI” scout sequence 
(18), which is commonly used in conjunction with late gadolinium enhanced MRI 





but also ECV measurements, as reported in this study. This implies that CMR researchers 
must consider the specific pulse sequence when translating published ECV cutoff values 
into their own studies. It also implies that the CMR community must work towards 
standardizing cardiac T1 and ECV mapping protocols, in order to move the field forward 
and increase reproducibility. The 2013 Society for Cardiovascular Magnetic Resonance 
and CMR Working Group of the European Society of Cardiology consensus statement 
(38) is one important step in the right direction towards protocol standardization.  
This study has several limitations worth noting. First, we did not test different 
variants of MOLLI (34,39), because our group has the most experience with the original 
version of MOLLI (i.e., 3-3-5) that was provided by Siemens. Another study is warranted 
to test the performance of different variants of MOLLI. Second, we did not compare 
other inversion-recovery and saturation-recovery based cardiac T1 mapping pulse 
sequences (11-14,17,18,40). Therefore, our observations may not be directly applicable 
for other pulse sequences not evaluated in this study. Our study adds to the growing list 
of studies which compare the performances of different cardiac T1 mapping pulse 
sequences (11,15,19,41,42). Third, the canines included in this study had a mean heart 
rate of 98.8 bpm, and pigs had a mean heart rate of 78.1 bpm. This implies that our 
observation may not be directly applicable for different heart rates and rhythm 
conditions. Fourth, the animals in this study did not have a prior history of heart disease 
(assumed to have normal myocardium and supported by ECV measurements). Therefore, 
our observations may not be directly applicable for hearts with focal and/or diffuse 
cardiac fibrosis, which changes post-contrast myocardial T1 and ECV values. Fifth, this 





histologic quantification of collagen volume fraction. A future study including 
comprehensive histologic evaluation is warranted to compare the accuracy of ECV 
measurements between MOLLI and AIR.   
 
5.5 Conclusions 
This study shows that MOLLI and AIR yield significantly different T1 and ECV 
values in large animals and that MOLLI yields higher precision than AIR. Both intra- and 
inter-observer agreements in calculation of T1 were higher for MOLLI than AIR, but 
intra- and inter-observer agreements in calculation of ECV were similar between MOLLI 
and AIR. Findings from this study suggest that CMR researchers must consider the 
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Table 5.1. Pair-wise t-test statistics comparing the different subgroups of T1 derived 
from MOLLI and AIR cardiac T1 mapping pulse sequences: native myocardial T1, 
native blood T1, post-contrast myocardial T1, and post-contrast blood T1. T1 value 



















Figure 5.1. Schematic of AIR (top row) and (bottom) MOLLI cardiac T1 mapping 
pulse sequences. AIR acquires one proton density and one T1-weighted image in 
succession with scan time of 2-3 heart beats, depending on heart rate as shown. 
MOLLI acquires 11 images with scan time of 17 heart beats, following three inversion 











Figure 5.2. Representative cardiac T1 maps of one dog (heart rate = 94.5 bpm) 
acquired with MOLLI (left) and AIR (right) cardiac T1 mapping pulse sequences: 
native (top row) and post-contrast (bottom row). These examples illustrate typical 
image quality produced by MOLLI and AIR. Compared with AIR T1 maps derived 
from only 2 images, MOLLI T1 maps derived from 11 images exhibited higher overall 
SNR. Native myocardial and blood T1 values were different (native myocardial T1 was 
1074.1 ms (MOLLI) and 1373.4 ms (AIR); native blood T1 was 1492.7 ms (MOLLI) 
and 1692.9 ms (AIR). Post-contrast myocardial T1 was also different (605.5 ms 
[MOLLI] and 724.5 ms [AIR]), but post-contrast blood T1 was not different (389.2 ms 
[MOLLI] and 384.8 ms [AIR]). These differences in T1 resulted in discordant ECV 








Figure 5.3. Scatter plots representing linear regression (left column) and Bland-
Altman (right column) analyses: T1 (top row) and ECV (bottom row) derived from 
MOLLI and AIR cardiac T1 mapping pulse sequences in 16 dogs. According to the 
linear regression and concordance correlation analyses, T1 values were strongly 
correlated (Pearson's correlation coefficient = 0.99, slope = 1.33, bias = -117.6 ms, p < 
0.0001; concordance correlation coefficient = 0.87). According to the Bland-Altman 
analysis, the mean difference in T1 was 179 ms (± 95% confidential interval (CI) = 
468/-109 ms), which corresponds to 18% of the mean T1 value (981 ms). For ease of 
interpretation, the Bland-Altman plot for T1 was displayed with y-axis ranging from -
1000 to 1000 ms (i.e., approximately -100 to 100 % of the mean value of 981 ms). 
According to the linear regression analysis, ECV values derived were moderately 
correlated (Pearson's correlation coefficient = 0.65, slope = 0.77, bias = 2.8%, p < 
0.001). According to the concordance correlation analysis, ECV values were weakly 
correlated (correlation coefficient = 0.43). According to the Bland-Altman analysis, 
the mean difference in ECV was -2.2% (± 95% CI = 1.5/-5.9%), which corresponds to 
10.8% of the mean ECV value (20.7%). For ease of interpretation, the Bland-Altman 
plot for ECV was displayed with y-axis ranging from -8 to 8% (i.e., approximately -40 











Figure 5.4. Scatter plots representing the intra- (top row) and inter-observer (bottom 
row) agreements in calculation of T1 derived from MOLLI (left column) and AIR 
(right column) data sets. For intra-observer agreement, the mean difference in T1 was 
0.6 ms (upper/lower 95% limits of agreement = 5.3/-4.0 ms) and 0.4 ms (upper/lower 
95% limits of agreement = 9.2/-8.5 ms) for MOLLI and AIR, respectively. For inter-
observer agreement, the mean difference in T1 was 0.009 ms (upper/lower 95% limits 
of agreement = 9.8/-9.8 ms) and 0.4 ms (upper/lower 95% limits of agreement = 22.7/-
21.9 ms) for MOLLI and AIR, respectively. Note that CR was lower MOLLI than 
AIR, suggesting higher overall SNR for MOLLI than AIR. For ease of interpretation, 
the Bland-Altman plots were displayed with y-axis ranging from -50 to 50 ms (i.e., 
approximately -5 to 5 % of the mean value of 1000 ms). Solid and dotted lines 









Figure 5.5. Scatter plots representing the intra- (top row) and inter-observer (bottom 
row) agreements in calculation of ECV derived from MOLLI (left column) and AIR 
(right column) data sets. For intra-observer agreement, the mean difference in ECV 
was -0.09% (upper/lower 95% limits of agreement = 0.5/-0.7%) and 0.02% 
(upper/lower 95% limits of agreement = 0.5/-0.4%) for MOLLI and AIR, respectively. 
For inter-observer agreement, the mean difference in ECV was -0.2% (upper/lower 
95% limits of agreement = 1.1/-1.6%) and -0.1% (upper/lower 95% limits of 
agreement = 1.4/-1.6%) for MOLLI and AIR, respectively. Note that CR was similar 
between MOLLI and AIR, possibly due to off-setting errors from multiple 
measurements. For ease of interpretation, the Bland-Altman plots were displayed with 
y-axis ranging from -4 to 4% (i.e., approximately -20 to 20 % of the mean value of 








WIDEBAND AIR CARDIAC T1 MAPPING PULSE SEQUENCE 
 
This chapter describes the development of a new wideband AIR cardiac T1 mapping 
pulse sequence for imaging patients with an implantable defibrillator. This work was 
published in "Wideband Arrhythmia-Insensitive-Rapid (AIR) Pulse Sequence for Cardiac 
T1 Mapping without Image Artifacts Induced by an Implantable-Cardioverter-
Defibrillator" Magnetic Resonance in Medicine 2015, Volume 74, Issue 2, Pages 336-
345. Reprinted with permission from Wiley Periodicals, Inc. 
 
6.1 Introduction 
Heart failure (HF) is a major healthcare problem that affects over 5 million 
Americans (1). Patients with advanced or end-stage HF (i.e., stage D according to the 
ACCF/AHA classification (2)) are characterized by marked symptoms at rest despite 
maximal medical therapy (3); consequently, they have a 1-year mortality rate of 
approximately 40-50% (4,5). While heart transplantation is a well-established treatment 
for improving both survival and quality of life for these patients (6), from healthcare’s 
perspective, it is unsustainable due to a continuing shortage of donor hearts (7). To 
address this imbalance, the 2013 ACC/AHA guideline (2) recommends left ventricular 





Unfortunately, current clinical risk scores and profiles provide poor discrimination 
between responders and non-responders to LVAD therapy.  
Cardiac fibrosis, as a marker of adverse structural remodeling, is a strong predictor of 
functional response to intervention (14). While myocardial biopsy is the current gold 
standard for assessment of fibrosis, it is rarely indicated due to its associated non-
negligible risk of complications and susceptibility to sampling errors. MRI is emerging as 
a reliable non-invasive test for myocardial biopsy (15) using cardiac T1 mapping (16-18) 
or extracellular volume (ECV) fraction (18-24) mapping pulse sequences. Unlike 
myocardial biopsy, these MRI methods provide a means to sample the whole heart non-
invasively. In the context of HF induced by non-ischemic cardiomyopathy, cardiac T1 
and ECV fraction mapping pulse sequences may be better than late gadolinium-enhanced 
(LGE) MRI for quantification of myocardial fibrosis burden.  
Because LVAD candidates (i.e., end-stage HF) typically have prophylactic 
implantable cardioverter-defibrillator (ICD) for prevention of sudden cardiac death 
and/or arrhythmia, a new pulse sequence needs to be developed to reduce measurement 
error due to ICD and/or arrhythmia. Despite the fact that MRI can be performed safely in 
most patients with cardiac devices at 1.5T (25,26), many patients who would derive 
benefit from MRI do not undergo MRI largely due to image artifacts arising from the 
ICD generator. Recently, the feasibility of wideband LGE MRI was demonstrated for 
assessment of focal fibrosis in patients with ICD (27-29), where "wideband" refers to the 
modified hyperbolic secant radio-frequency (RF) pulse used to invert the magnetization 
in the presence of ICD. To our knowledge, no other study has reported successful cardiac 





Among the different cardiac T1 mapping pulse sequences, an arrhythmia-insensitive-
rapid (AIR) cardiac T1 mapping pulse sequence (30) with a short scan time (~2-3 heart 
beats) is well suited for imaging patients with advanced HF, because they often have 
rapid heart rates and/or irregular heart rhythm and/or limited breath-hold capacity. In this 
study, we will extend AIR cardiac T1 mapping to be insensitive to ICD, by incorporating 
a saturation RF pulse with wide frequency bandwidth to achieve uniform T1 weighting in 
the heart with ICD. We demonstrate the feasibility of wideband AIR cardiac T1 mapping 
and evaluate its relative accuracy in phantom and human experiments at 1.5T.  
 
6.2 Methods 
6.2.1 Saturation pulse modules  
As previously described in (30), the original AIR cardiac T1 mapping pulse sequence 
was implemented with balanced steady-state free precession (b-SSFP) readout. This pulse 
sequence acquires two single-shot images, T1-weighted and proton density (PD), within a 
scan time of 2-3 cardiac cycles, depending on heart rate. To minimize image artifacts 
induced by ICD and enable successful imaging of patients with ICD implantation, we 
modified the original AIR pulse sequence to use ultra-fast gradient echo (TurboFLASH 
in Siemens; FastSPGR in GE; TFE in Philips) readout. We used the vendor’s saturation 
pulse module for original AIR, which is comprised of three 90 rectangular pulses with 
0.5 ms duration for each rectangular RF pulse (see Figure 1A in (31)). We used this 
modified AIR pulse sequence (i.e., TurboFLASH readout + vendor saturation pulse 
module) as a reference to compare the wideband AIR pulse sequence described below. 





ICD generator is typically implanted on the patient’s left shoulder, approximately 5-
10 cm away from the heart. This distance will induce a center frequency shift as large as 
2-6 kHz (27). Standard saturation pulse modules have relatively low frequency 
bandwidth and, therefore, are unsuitable for complete saturation of magnetization in the 
presence of ICD. This means that an effective saturation RF pulse for wideband AIR 
cardiac T1 mapping in patients with ICD should have a frequency bandwidth greater than 
6 kHz to achieve uniform T1 weighting. One promising RF pulse module that can 
effectively saturate the magnetization over a wide range of frequencies is RF field (B1) 
insensitive train to obliterate signal (BISTRO)(32), which was originally developed for 
outer volume suppression in inhomogeneous B1. The primary concept behind BISTRO is 
to not meet the adiabatic condition on purpose for each individual inversion RF pulse 
(i.e., < 180 excitation per pulse), but ultimately fully rotate the longitudinal 
magnetization (Mz) onto the transverse plane (i.e., net excitation equal to 90) with a train 
of sub-optimal inversion RF pulses, where key design considerations are the number of 
pulses, frequency bandwidth, total pulse duration, and specific absorption rate (SAR). 
Figure 6.1 shows the pulse sequence diagram of BISTRO that was incorporated into AIR. 
See Appendix for more details on our implementation of BISTRO. For clarity, AIR with 
BISTRO is referred to as wideband AIR throughout this report. 
 
6.2.2 Calculation of RF energy deposition by the saturation pulse modules  
Using the pulse sequence simulator (IDEA, Siemens Healthcare, Erlangen, 
Germany), we calculated the transmit RF energy for each saturation pulse module, 





of 500 Hz is 300-350 V. This RF calibration assumption at 1.5T is consistent with results 
reported in (33). Nominal B1+ (normalized by gyromagnetic ratio) is 500 Hz (300-350 V) 
for the original saturation pulse module, whereas nominal B1+ (normalized by 
gyromagnetic ratio) is 926 Hz (556-648 V) for the wideband saturation pulse module. 
Note the RF amplifier of our Siemens Espree system delivers a maximum voltage of 949 
V. At these settings, theoretically calculated transmit RF energy of original and wideband 
saturation pulse modules was 3.7 and 101.0 J, respectively. These energy deposition 
values translate to whole-body SAR of approximately 0.125 and 0.5 W/kg for original 
and wideband AIR T1 mapping acquisitions, respectively, depending on subject size. We 
note that this SAR calculation includes saturation pulse and RF excitations for PD and 
T1-weighted image acquisitions. This theoretical analysis confirms that whole-body SAR 
induced by wideband AIR is 3-4 times lower than the safe limits (1.5-2 W/kg) 
recommended by established pacemaker/ICD MRI protocols at 1.5T (25,26).  
  
6.2.3 Calculation of frequency bandwidth of the saturation pulse modules  
We determined empirically, in a phantom positioned near magnet isocenter, 
frequency bandwidth of the original and wideband saturation pulse modules. Compared 
with original AIR, wideband AIR had 256% higher frequency bandwidth (full width at 
half maximum [FWHM] = 2.5 kHz and 8.9 kHz for original and wideband, respectively). 
For more details on the methods and results, see 6.5 Supplementary Materials and Figure 
6.2A. This experimental analysis confirms that wideband AIR is insensitive to center 
frequency shift expected with ICD located 5-10 cm away from the heart.  





The original and wideband AIR cardiac T1 mapping pulse sequences were 
implemented on a 1.5T whole-body MRI scanner (Espree, Siemens Healthcare, Erlangen, 
Germany), equipped with a gradient system capable of achieving a maximum gradient 
strength of 33 mT/m and a slew rate of 100 T/m/s. RF excitation was performed using the 
body coil, and an 8-element coil array was used for signal reception.  
Both original and wideband AIR pulse sequences used the following relevant imaging 
parameters: field of view = 360 mm × 270 mm (phase-encoding), acquisition matrix = 
128 × 96 (phase-encoding), in-plane resolution = 2.8 mm × 2.8 mm, slice thickness = 8 
mm, echo time (TE) = 1.1 ms (asymmetric readout), repetition time (TR) = 2.2 ms, 
receiver bandwidth = 1000 Hz/pixel, center-out k-space ordering, readout duration = 132 
ms, saturation-recovery time delay (TD) = 600 ms, flip angle = 10°, breath-hold duration 
= 2-3 heart beats, and generalized autocalibrating partially parallel acquisitions 
(GRAPPA)(34) with an acceleration factor = 1.6 (including reference lines). Note that in 
center-out k-space ordering the first RF excitation is used to acquire the origin of k-space. 
This acquisition scheme minimizes the sensitivity to excitation angle variation (35,36) 
and enables straight-forward calculation of T1 using the Bloch equation describing ideal 
saturation-recovery, as previously described (30).   
 
6.2.5 Experiment 1: Evaluation of sensitivity to ICD and intracardiac  
leads in phantom  
We evaluated the performance of original and wideband AIR pulse sequences with 
and without an ICD generator (Vitality AVT Model A155, GUIDANT Boston Scientific, 





performed T1 mapping in a coronal plane with the ICD in the plane, in order to visualize 
the effectiveness of the saturation pulse modules as a function of ICD distance. We also 
performed a static magnetic field (B0) mapping acquisition (i.e., double echo with TE 
difference = 4.76 ms) with matching spatial resolution as T1 mapping. For cases with 
ICD, the B0 maps were generated after performing phase unwrapping based on network 
programming (37). The same experiment was repeated with intracardiac leads attached to 
the same location. In this experiment, original AIR cardiac T1 mapping without ICD was 
used as the control. 
 
6.2.6 Experiment 2: Evaluation of accuracy in MnCl2 phantoms with ICD  
We tested the performance of original and wideband AIR cardiac T1 mapping pulse 
sequences in phantoms with clinically relevant T1 and T2 values positioned near magnet 
isocenter. Specifically, we imaged five phantoms with different concentrations of 
manganese (II) chloride (MnCl2) in distilled water (see Table 1 for the concentration and 
reference T1 and T2 values). MnCl2 was chosen because it has T1/T2  10 at 1.5 T (38), 
which is comparable to that of tissues.  
Reference T1 values were measured using an inversion-recovery fast spin echo (IR-
FSE) pulse sequence; the resulting data were analyzed using a 2-parameter fit of the 
mono-exponential signal relaxation, solving for equilibrium signal amplitude and T1.. The 
relevant imaging parameters for IR-FSE include: same spatial resolution as AIR, 
excitation flip angle = 90º, refocusing flip angle = 180, TE = 6 ms, TR = 20 s (> 5 T1s), 
receiver bandwidth = 501 Hz/pixel, turbo factor = 7, and number of images = 16. The 





1800, 2300, 2700, and 20000 ms.  
For comparison, we also performed 3-3-5 modified Look-Locker inversion recovery 
(MOLLI)(39) with b-SSFP readout and heart rate simulated to 60 beats per minute. The 
relevant imaging parameters for 3-3-5 MOLLI include: same spatial resolution as AIR, 
scan time = 17 heart beats, flip angle = 35º, TE = 1.1 ms, TR = 2.6 ms, receiver 
bandwidth = 930 Hz/pixel, and inversion times and linear k-space ordering as previously 
described (39).  
Reference T2 values were measured using a multi-echo fast spin echo (ME-FSE) 
pulse sequence (40); the resulting data were analyzed using a 3-parameter fit of the 
mono-exponential signal relaxation, solving for initial signal amplitude, T2, mean 
background noise. The relevant imaging parameters for ME-FSE include: same spatial 
resolution as AIR, excitation flip angle = 90º, refocusing flip angle = 180, TR = 20 s (> 
5 T1s), receiver bandwidth = 501 Hz/pixel, turbo factor = 2, inter-echo spacing = 4.7 ms, 
inter-image spacing = 9.4 ms, and number of images = 12. The image echo times were 
9.4, 19, 28, 38, 47, 57, 66, 76, 85, 95, 104, and 113 ms. 
For each phantom vial, with the ICD generator taped 10 cm away from the phantom 
vial (through-plane direction), we performed original and wideband AIR T1 mapping 
acquisitions. This experiment was repeated without ICD for completeness. 
 
6.2.7 Experiment 3: Evaluation of accuracy in MnCl2 phantoms  
as a function of center frequency shift 
We evaluated the performance of original and wideband AIR in phantoms (same as 





Bandwidth experiment; see 6.5 Supplementary Materials).   
 
6.2.8 Experiment 4: Evaluation of accuracy in human subjects with ICD  
Human imaging was conducted in accordance with protocols approved by our 
institutional Review Board and the Health Insurance Portability and Accountability Act; 
all subjects provided written informed consent. 
We evaluated the performance of original and wideband AIR cardiac T1 mapping 
pulse sequences in 11 human volunteers (10 males, 1 female, mean age = 30.0 ± 6.0 
years) without prior history of heart disease. In each subject, we conducted T1 mapping in 
2-chamber and short-axis planes of the left ventricle, without administration of contrast 
agent (i.e., native T1 mapping). To mimic image artifacts induced by ICD, we taped the 
ICD generator on each subject's left shoulder, approximately 5-10 cm superior to the left 
nipple, and performed original and wideband AIR cardiac T1 mapping acquisitions. This 
mimicking approach (taping an ICD on left shoulder) was first established by Rashid et 
al. at 1.5T (27) and verified by our group at 3T (29). In human experiments, original AIR 
cardiac T1 mapping without ICD was used as the control (see phantom results in Table 
6.1 for justification).  
In one male volunteer (age = 37), we performed native and post-contrast (15 and 35 
min after administration of 0.15 mmol/kg of MultiHance) cardiac T1 mapping in a 2-
chamber plane of the left ventricle. This experiment was conducted to verify insensitivity 
to clinically relevant T2. For each time point (baseline and 15 and 35 min after 
administration of MultiHance), we performed original and wideband AIR T1 mapping 





original AIR with ICD, wideband AIR, and wideband AIR with ICD) per time point. For 
each time point, we first randomized the ICD presence, and then randomized the pulse 
sequence order. To further reduce the impact of contrast agent washout effects, we 
streamlined the protocol to perform 4 T1 mapping acquisitions per time point in 1 min 
(including breathing instructions), while making sure to allow full magnetization 
recovery between acquisitions (i.e., wait time > 5 T1s). To maintain the same ICD 
position throughout MRI at different time points, we drew the contour of the ICD on the 
volunteer's chest for repeatable taping and removal. 
 
6.2.9 Image analysis 
To achieve noise reduction during post-processing, which is important since low 
signal-to-noise ratio is expected with ultra-fast gradient echo readout and 10 flip angle, 
we applied a modified Hanning window to the k-space representation of each image. To 
estimate the blurring effects of the Hanning window, we calculated its point spread 
function (PSF) as the inverse Fourier transform of the window. We then calculated the 
FWHM with subpixel precision using linear interpolation. The resulting FWHM was 1.5 
and 1.3 pixel in the frequency-encoding and phase-encoding directions, respectively. 
Note that FWHM of an ideal PSF is 1 pixel.  
For calculation of T1, the T1-weighted image was divided by the corresponding PD 
image on a pixel-by-pixel basis, and the ratio was used to calculate T1 based on the Bloch 
equation describing T1 relaxation in ideal saturation-recovery, as previously described 
(30). For the phantom experiments, we generated a mask defining the phantom boundary 





phantom. For cardiac data analysis, endo- and epi-cardial contours were manually drawn 
to segment the myocardium, and another region-of-interest (ROI) was drawn to encircle 
the LV cavity. Care was taken to avoid partial volume averaging for each contour tracing 
(see Figure 6.4). All image processing was conducted using customized software 
programmed in Matlab (R2009a, The MathWorks, Inc., Natick, MA).  
 
6.2.10 Statistical analysis 
For statistical analysis of human data from 11 subjects, for each measurement type 
(native blood, native myocardium) per cardiac plane (short-axis, 2-chamber view), the 
mean T1 value within an ROI (blood or myocardium) was pooled and averaged over 11 
subjects. For each measurement type per cardiac plane, a single-factor analysis of 
variance was used to compare the mean T1 values between four groups (original AIR 
without ICD, original AIR with ICD, wideband AIR without ICD, and wideband AIR 
with ICD), and Bonferroni correction was used to compare the mean values between the 
control (original AIR without ICD) and other three groups (original AIR with ICD, 
wideband AIR without ICD, and wideband AIR with ICD). A p < 0.05 was considered to 
be significant. All statistical analyses were performed using the Analyse-it software 











6.3.1 Experiment 1: Evaluation of sensitivity to ICD and intracardiac  
leads in phantom  
Figure 6.3 shows coronal T1 maps of a phantom with ICD taped on one side of the 
phantom as shown. A T1 map acquired with original AIR without ICD is also shown as 
the reference. Original AIR with ICD yielded considerable image artifacts, whereas 
wideband AIR with ICD suppressed image artifacts in regions as shown. Figure 6.3 also 
shows the corresponding T1 maps with intracardiac leads attached to the same location as 
ICD. Note that both original and wideband AIR were insensitive to intracardiac leads. 
 
6.3.2 Experiment 2: Evaluation of accuracy in MnCl2 phantoms with ICD  
In 5 phantoms with different concentrations of MnCl2, compared with the control T1 
values derived from IR-FSE without ICD, the corresponding T1 values were considerably 
lower for original AIR with ICD, whereas the T1 values were similar for wideband AIR 
with ICD. For completeness, see the corresponding T1 results for original and wideband 
AIR and MOLLI without ICD (Table 6.1). We note that the standard deviation per 
phantom is considerably higher for original AIR with ICD than wideband AIR with ICD, 
implying higher sensitivity to ICD for original AIR.  
 
6.3.3 Experiment 3: Evaluation of accuracy in MnCl2 phantoms  
as a function of center frequency shift  
Figure 6.2B shows plots of T1 as a function of center frequency shift. Consistent with 





8.9 kHz, whereas original AIR produced consistent T1 results over 2.5 kHz.   
 
6.3.4 Experiment 4: Evaluation of accuracy in human subjects with ICD  
Figure 6.4 shows representative native T1 maps in short-axis and long-axis planes of 
the heart of two different volunteers. Compared with original AIR without ICD as the 
control, original AIR with ICD produced less accurate T1 results, whereas wideband AIR 
with ICD produced more accurate T1 results. For completeness, see the corresponding T1 
results for original and wideband AIR without ICD (Table 6.S1 in 6.5 Supplementary 
Materials). We note that the standard deviation per ROI is considerably higher for 
original AIR with ICD than wideband AIR with ICD, implying higher sensitivity to ICD 
for original AIR. 
Averaging the results over 11 human subjects, the mean myocardial and blood T1 
measurements were significantly different between the four groups (Table 6.2; p < 
0.001). Compared with original AIR without ICD as the control, only original AIR with 
ICD was significantly different in both imaging planes (p < 0.05). We note that native T1 
measurements (myocardial T1 ~ 1,100 ms; blood T1 ~ 1,500 ms) made with original AIR 
without ICD and wideband AIR with and without ICD are comparable to ex-vivo (41) 
and in vivo (42) myocardial and blood T1 measurements at 1.5T reported in literature.  
Figure 6.5 shows native and post-contrast T1 maps of another volunteer. Similar to 
the results shown in Figure 6.4 and data summarized in Table 6.1, compared with original 
AIR without ICD, original AIR with ICD produced less accurate T1 results, whereas 
wideband AIR with ICD produced more accurate T1 results. For completeness, see the 





Supplementary Materials). Consistent with phantom and native cardiac T1 results, the 
standard deviation per ROI is considerably higher for original AIR with ICD than 
wideband AIR with ICD, implying higher sensitivity to ICD for original AIR. 
 
6.4 Discussion 
This study demonstrates the feasibility of a wideband pulse sequence for cardiac T1 
mapping without significant image artifacts induced by ICD at 1.5T. In both phantom and 
human experiments, compared with control T1 measurements without ICD, original AIR 
with ICD produced less accurate T1 results, whereas wideband AIR with ICD produced 
more accurate T1 results.  
This study has several points that warrant discussion. First, to our knowledge, this is 
the first study reporting successful cardiac T1 mapping without significant image artifacts 
induced by ICD. Future studies include evaluation of diffuse myocardial fibrosis burden 
in patients with ICD implantation. Second, in addition to the image artifacts that cause T1 
error, ICD may also cause severe image distortion, spatial shifts, and signal loss due to 
intravoxel dephasing, all of which may be a problem when registering different MR 
images which have different sensitivities. These effects can be minimized by using a 
readout with short echo time such as ultra-short TE pulse sequences. Third, compared 
with original AIR, wideband AIR deposits more energy per unit time (i.e., higher SAR). 
However, in the context of wideband AIR cardiac T1 mapping (one PD image acquisition 
without saturation pulse and one T1-weighted image acquisition with saturation pulse, 
each acquisition with TurboFLASH readout), we were able to perform wideband AIR 





limits (1.5-2 W/kg) recommended by established pacemaker/ICD MRI protocols at 1.5T 
(25,26). Therefore, it is highly unlikely that wideband AIR will cause significant lead tip 
heating. Nevertheless, a future comprehensive study is warranted to measure RF-induced 
lead tip heating with wideband AIR, similar to (43,44). Fourth, this study did not test 
other investigational cardiac T1 mapping pulse sequences in the presence of ICD. Other 
investigational cardiac T1 mapping pulse sequences (MOLLI (39) and ShMOLLI (45) 
using a standard hyperbolic secant adiabatic inversion RF pulse; SASHA (42) and 
MLLSR (46) using a standard saturation pulse) are likely to be sensitive to ICD and 
produce inaccurate T1 results, because the frequency bandwidth of the aforementioned 
RF pulse modules is not wide enough to handle the large center frequency shift induced 
by ICD. In addition, MOLLI, ShMOLLI, MLLSR, and SASHA all use b-SSFP, so the 
readout will also generate image artifacts induced by ICD. Therefore, we did not compare 
wideband AIR with MOLLI, ShMOLLI, MLLSR, and SASHA, since their wideband 
counterparts are currently unavailable. A head-to-head comparison between wideband 
AIR to wideband versions of MOLLI, ShMOLLI, MLLSR, and SASHA (which currently 
do not exist) is beyond the scope of this study. Fifth, we note that both original (FWHM 
= 2.5 kHz) and wideband (FWHM = 8.9 kHz) saturation pulse modules are insensitive to 
typical static magnetic field inhomogeneity in the heart at 1.5T (~ 100 Hz, largely due to 
the heart-lung interface and/or cardiac veins)(47). Sixth, while duration of the wideband 
pulse module is 151 ms, the total RF time is only 46 ms, whereas the remaining time is 
used to play crusher and spoiler magnetic field gradients. We note that in the context of 
saturation of magnetization, T2 relaxation during the RF time is a benefit, whereas in the 





insensitive to T2 in the context of saturation recovery of magnetization (see Table 6.1 and 
Figure 6.5).  
This study has three limitations that warrant discussion. First, as a technical 
development work, we did not include patients with ICD implantation. A thorough 
investigation of safety and effectiveness in patients with ICD implantation is beyond the 
scope of this work. As such, we are unable to definitively claim that wideband AIR is 
insensitive to implanted ICD including intracardiac leads. Our phantom study (see Figure 
6.3) shows that intra-cardiac leads do not produce significant image artifacts. 
Furthermore, our experience with LGE MRI (with a standard hyperbolic secant inversion 
pulse with frequency bandwidth ~ 1 kHz) in patients with ICDs suggests that the center 
frequency shift induced by intracardiac leads is not high enough to influence the efficacy 
of a standard hyperbolic secant inversion pulse. Our experience is consistent with 
wideband LGE MRI results reported by Rashid et al. (27). The mimicking approach 
(taping an ICD generator on the subject's left shoulder) was first established by Rashid et 
al. at 1.5T (27) and verified by our group at 3T (29). Thus, results from this study are 
likely to translate to patients with ICD implantation. Not testing the performance of 
wideband AIR cardiac T1 mapping in patients with ICD implantation is a limitation of 
this study; on the other hand, the proposed study design, with original AIR T1 mapping 
without ICD as the control, allows reference measurements and repeated measurements 
without safety concerns associated with lead tip heating. This technical development 
work may set the foundation for future studies aim at evaluating both the effectiveness 
and safety of wideband AIR cardiac T1 mapping in patients with implanted cardiac 





2.8 mm × 2.8 mm (4.2 mm × 3.6 mm accounting for the additional blurring caused by 
Hanning window), in order to compensate for low signal-to-noise ratio. Compared with 
3-3-5 MOLLI, wideband AIR is expected to produce lower signal-to-noise ratio (see 
standard deviation values in Table 6.1) due to the following factors: b-SSFP (MOLLI) vs. 
TurboFLASH (wideband AIR), inversion recovery (MOLLI) vs. saturation recovery 
(wideband AIR), and 11 images (MOLLI) vs. 2 images (wideband AIR). The resolution 
used in this study will be sensitive to partial volume effects and introduce errors when 
quantifying T1 from small myocardial lesions. Fortunately, the spatial resolution reported 
in this study may be adequate for quantifying diffuse cardiac fibrosis in patients with 
non-ischemic cardiomyopathy. Potential approaches to improve the spatial resolution 
include the use of dedicated cardiac coil array and image denoising with nonlinear 
iterative method such as non-local means (49). Third, this study included only one 
subject with contrast agent administration. Consistent with BISTRO characteristics (see 
6.5 Supplementary Materials), our phantom study (see Table 6.1) shows that wideband 
saturation pulse module is insensitive to T2. While both theoretical and in vitro results 
suggest insensitivity to T2, additional human subjects with contrast agent administration 
need to be examined to verify that wideband is insensitive to clinically relevant T2.  
In summary, this study demonstrates the feasibility of wideband AIR pulse sequence 
for cardiac T1 mapping without significant image artifacts induced by ICD. A future 
study of a high number of patients with ICD implantation is warranted to evaluate the 
clinical utility of wideband AIR cardiac T1 mapping for assessment of myocardial 
fibrosis burden without image artifacts induced by ICD. This new cardiac-device-





has the potential to activate new clinical studies aimed at advancing other cardiac devices 
such as biventricular pacemaker. 
 
6.5 Supplementary Materials 
6.5.1 BISTRO implementation details 
We implemented BISTRO as a train of 15 hyperbolic secant adiabatic inversion RF 
pulses, with crusher gradients in between RF pulses to minimize stimulated echoes, and 
spoiler gradients before the first RF pulse and after the last RF pulse to dephase the 
transverse magnetization (see Figure 6.1). We decreased the duration from the first to last 
set of crusher gradients to suppress stimulated echoes. The total duration, including 
crusher and spoiler gradients, was 151 ms. Each hyperbolic secant inversion pulse 
(frequency modulation parameter  = 750 radians/s, phase modulation parameter = 10 
[dimensionless]) was 3.07 ms long and its nominal transmit B1+ (normalized by 
gyromagnetic ratio) calibrated by the transmit body coil was 926 Hz. The number of 
pulses and nominal B1+ (i.e., amplitude) for each pulse were empirically determined in a 
preliminary phantom experiment, where we systematically adjusted the number of RF 
pulses and nominal B1+ to consistently achieve effective saturation of magnetization (i.e., 
residual Mz immediately after the last RF pulse in the module is less than 5% of 
equilibrium magnetization (M0)). 
 
6.5.2 Calculation of frequency bandwidth of the saturation pulse modules  
We determined empirically, in a phantom positioned near magnet isocenter, the 





approach described in (31,48,50), we quantified the residual Mz immediately after the 
saturation pulse module, by normalizing the saturation-no-recovery image (i.e., TD = 3 
ms, which is the duration of the spoiler gradients) with the PD image (i.e., M0) and 
calculating the residual Mz as a fraction of M0 (0 to 1). Note that residual Mz of 0 
corresponds to complete saturation of magnetization, whereas residual Mz of 1 
corresponds to no rotation. The experiment was repeated by adjusting the center 
frequency offset of the saturation pulse module from -6 to 6 kHz (variable steps). We 
then plotted the residual Mz (as a fraction of M0) as a function of center frequency shift to 
calculate the FWHM, which is by definition the frequency bandwidth of the saturation 
pulse module. As shown in Figure 6.2, the residual Mz curve for original saturation pulse 
module had side lobes. This observation is consistent with the fact that original saturation 
pulse module is comprised of 3 rectangular RF pulses (i.e., Fourier transform of a 
rectangular function is a sinc; see Figure 6.2). 
 
6.5.3 Supporting information 
See Table 6.S1. 
See Table 6.S2. 
See Figure 6.S1. 
 
6.6 Clinical Testing in Patients with a Defibrillator 
As a follow-up to the development of the wideband AIR cardiac T1 mapping pulse 
sequence, we tested its performance in several patients with implantable defibrillators. 





post-contrast T1 maps, where wideband AIR produced considerably lower image artifacts 
than original AIR. 
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Table 6.1. Summary of T1 measurements of five MnCl2 phantoms representing native 
myocardium (1,174 ms) and blood (1,550 ms) and post-contrast (500, 549, and 755 
ms) blood/tissue T1 values. Values represent mean ± standard deviation within an 
ROI. Percent error (relative to IR-FSE without ICD) is reported in parenthesis. Note 
that the standard deviation within an ROI is larger for original AIR with ICD than the 
other three AIR acquisitions (original AIR without ICD, wideband AIR without ICD, 




















Table 6.2. Summary of mean myocardial and blood T1 measurements over 11 human 
subjects. These T1 measurements were made with original AIR without ICD, 
wideband AIR without ICD, original AIR with ICD, and wideband AIR with ICD. 
Values represent mean ± standard deviation over 11 subjects. Percent error (relative to 
original AIR without ICD) is reported in parenthesis. Myocardial T1 was significantly 
(p < 0.001) different between four acquisitions in 2-chamber and short-axis planes. 
Compared with original AIR without ICD as the control, only original AIR with ICD 
was significantly different in both imaging planes (p < 0.05). The same trends were 
observed for blood T1 (ANOVA; p < 0.001), where only original AIR with ICD was 
significantly different from original AIR without ICD in both imaging planes (p < 
0.05). We regret that the Analyse-it software does not report the adjusted p values for 
the Bonferroni paired-wise test. 2-CH: 2-chamber view; SAX: short-axis view.  







Table 6.S1. Summary of myocardial and blood T1 measured by original AIR without 
ICD, wideband AIR without ICD, original AIR with ICD, and wideband AIR with ICD, 
for two representative volunteers shown in Figure 6.4. V1: volunteer 1; V2: volunteer 2; 
2-CH: 2-chamber view; SAX: short-axis view. Values represent mean ± standard 
deviation within ROI. Percent error (relative to original AIR without ICD) is reported in 
parenthesis. Note that the standard deviation is larger for original AIR with ICD than the 
other three AIR acquisitions. 
 
Tissue Type Original (ms) Wideband (ms) 






1131.1 ± 94.0 1170.0 ± 102.5 (3.4%) 
931.5 ± 249.0 
(-17.6%) 




1114.0 ± 67.5 1131.9 ± 63.3 (1.6%) 
838.6 ± 262.3 
(-24.7%) 




1514.9 ± 89.6 1471.4 ± 79.9 (-2.9%) 
1424.6 ± 132.9 
(-6.0%) 




1533.8 ± 86.6 1508.0 ± 65.8 (-1.7%) 
1322.3 ± 205.0 
(-13.8%) 




1094.2 ± 100.7 1173.6 ± 132.1 (7.3%) 
769.6 ± 302.2 
(-29.7%) 




1113.2 ± 110.0 1120.7 ± 113.6 (0.7%) 
634.5 ± 264.6 
(-43.0%) 




1499.3 ± 103.0 1501.4 ± 101.7 (0.1%) 
1129.7 ± 283.2 
(-24.6%) 




1568.4 ± 95.9 1574.3 ± 67.7 (0.4%) 
1290.3 ± 127.3 
(-17.7%) 

















Table 6.S2. Summary of native and post-contrast myocardial and blood T1 measurements 
of 1 volunteer (see Figure 6.5). These T1 measurements were made by original AIR 
without ICD, wideband AIR without ICD, original AIR with ICD, and wideband AIR 
with ICD. Values represent mean ± standard deviation within ROI. Percent error (relative 
to original AIR without ICD) is reported in parenthesis. Note that the standard deviation 




Original (ms) Wideband (ms) 






1101.4 ± 87.8 1174.9 ± 98.4 (6.7%) 
950.7 ± 240.6 
(-13.7%) 
1156.2 ± 77.1 (5.0%) 
15 min, 
myocardium 
457.6 ± 35.6 456.9 ± 43.4 (-0.2%) 
408.8 ± 72.5 
(-10.7%) 
455.8 ± 44.0 (-0.4%) 
35 min, 
myocardium 
511.5 ± 38.4 527.3 ± 33.8 (3.1%) 
476.0 ± 80.8 
(-6.9%) 
520.7 ± 48.5 (1.8%) 
Native, blood 1488.2 ± 102.2 1529.1 ± 100.8 (2.7%) 
1336.5 ± 182.3 
(-10.2%) 
1498.0 ± 99.5 (0.7%) 
15 min, blood 225.3 ± 34.7 212.8 ± 29.0 (-5.6%) 
212.9 ± 39.3 
(-5.5%) 
219.9 ± 30.5 (-2.4%) 
35 min, blood 295.5 ± 24.8 296.2 ± 28.9 (0.2%) 
285.5 ± 31.7 
(-3.4%) 










Figure 6.1. Pulse sequence diagram of a wideband saturation pulse module 
(BISTRO), which is comprised of 15 hyperbolic secant inversion RF pulses that do 
not meet the adiabatic condition on purpose. The spoiler gradients are applied before 
the first RF pulse and after the last RF pulse to dephase the transverse magnetization. 
The crusher gradients in between RF pulses are played to minimize stimulated echoes. 
While duration of the wideband saturation pulse module is 151 ms, the total RF time is 
only 46.05 ms, whereas the remaining time is used to play crusher and spoiler 
magnetic field gradients. These diagrams are drawn to approximate proportions but 










Figure 6.2. (A) Plots of residual Mz (as a fraction of M0) as a function of center 
frequency shift. Note that residual Mz = 0 corresponds to complete saturation of 
magnetization, whereas residual Mz = 1 corresponds to no saturation. Compared with 
the original saturation pulse module (gray line), wideband pulse module (black line) 
had 256% higher frequency bandwidth (FWHM = 2.5 kHz and 8.9 kHz for original 
and wideband, respectively). f = center frequency shift. (B) Plots of T1 as a function 
of center frequency shift. Consistent with the frequency bandwidth experiment, 
wideband AIR (black line) produced consistent T1 results over 8.9 kHz, whereas 









Figure 6.3. Coronal T1 maps of a phantom acquired with original AIR (left column) 
and wideband AIR (right column): without anything taped (top row), with ICD leads 
(middle row), and with ICD taped on one side of the phantom as shown (bottom row). 









Figure 6.4. Representative native T1 maps in short-axis (rows 2 and 4) and long-axis 
(rows 1 and 3) planes of the heart of two different volunteers with and without ICD 
taped on their left shoulder (~5-10 cm from the heart): original AIR without ICD 
(column 1), wideband AIR without ICD (column 2), original AIR with ICD (column 
3), and wideband AIR with ICD (column 4). Compared with original AIR without 
ICD as the control, original AIR with ICD produced less accurate T1 results, whereas 
wideband AIR with ICD produced more accurate T1 results. White arrows point to 
cardiac regions compromised by ICD. Blood and cardiac contours superimposed on 
the left column only. See Table 6.S1 in 6.5 Supplementary Materials for the 








Figure 6.5. Representative native and post-contrast (15 and 35 min after MultiHance 
administration) T1 maps in a 2-chamber plane of the heart acquired with and without 
ICD taped on his left shoulder (~5-10 cm from the heart): original AIR without ICD 
(column 1), wideband AIR without ICD (column 2), original AIR with ICD (column 
3), and wideband AIR with ICD (column 4). Compared with original AIR without 
ICD as the control, original AIR with ICD produced less accurate T1 results, whereas 
wideband AIR with ICD produced more accurate T1 results. White arrows point to 
cardiac regions compromised by ICD. See Table 6.S2 in 6.5 Supplementary Materials 















Figure 6.6. Original (left column) and wideband (right column) AIR post-contrast T1 
maps in patient 1 with an ICD (top row) and patient 2 with a subcutaneous ICD (S-









Figure 6.S1. Plots of T1 as a function of center frequency offset, corresponding to 
results shown in Figure 6.3: original AIR (left) and wideband AIR (right). Each point 








This dissertation described advanced cardiac T1 mapping pulse sequences for 
quantification of diffuse myocardial fibrosis in LVAD candidates. Our new methods 
addressed three major obstacles for successful MRI in LVAD candidates: arrhythmia, 
limited breath-hold capacity, and implantable defibrillators.    
 
7.1 Summary of Work 
Novel cardiac T1 mapping methods have been developed and evaluated for 
quantification of diffuse myocardial fibrosis in LVAD candidates. First, to overcome 
arrhythmia and limited breath-hold capacity, an AIR cardiac T1 mapping pulse sequence 
was developed (Chapter 3), validated against histology (Chapter 4), and compared with 
MOLLI (Chapter 5). Second, to overcome the challenge of suppressing image artifacts 
induced by implantable defibrillators, a wideband AIR cardiac T1 mapping pulse 
sequence was developed and tested in healthy volunteers and patients with a device 







7.2 Future Work 
As part of Dr. Kim’s research sponsored by the NIH (R01HL123003-01A1), we will 
continue to optimize AIR cardiac T1 mapping beyond what is described in this 
dissertation. We will also take additional steps to examine whether pre-existing 
myocardial fibrosis predicts poor LV functional recovery following LVAD implantation.  
First, we will develop a free-breathing method applicable to both the original and 
wideband AIR cardiac T1 mapping pulse sequences. Leveraging the simple imaging 
strategy of the AIR method, one proton-density image and multiple T1-weighted images 
can be consecutively acquired during a free-breathing examination, until good 
registration between them is achieved (1). In conjunction with the free-breathing method, 
image post-processing techniques such as diffeomorphic registration (2) can be used as a 
complementary approach (3). 
Second, we will improve the reliability of the original and wideband AIR cardiac T1 
mapping pulse sequences. Through pulse sequence optimizations, these pulse sequences 
can achieve superior precision and performance. For example, "centric-pair" k-space 
ordering and high flip angles will improve precision in the AIR method and achieve  
similar repeatability as MOLLI (article in press (4)). Optimization of the wideband RF 
pulse will improve the homogeneity of the RF field and minimize SAR (5), improving 
the reliability of T1 measurements with the wideband AIR method.  
Third, we will investigate whether pre-existing myocardial fibrosis predicts poor LV 
functional recovery following LVAD-induced unloading. In each LVAD candidate with 
non-ischemic cardiomyopathy, we will conduct a CMR scan for quantification of pre-




LVAD surgery. Six months after starting the LVAD-induced mechanical unloading (6), 
each patient will undergo a repeat test for measuring the heart function, in order to 
determine the degree of cardiac functional improvement compared to baseline. In 
addition, we will validate the wideband AIR cardiac T1 mapping pulse sequence against 
histology, because the apical myocardium can be sampled during LVAD surgery.     
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